US20110020451A1 - Tamper-resistant dosage form for oxidation-sensitive opioids - Google Patents

Tamper-resistant dosage form for oxidation-sensitive opioids Download PDF

Info

Publication number
US20110020451A1
US20110020451A1 US12840471 US84047110A US2011020451A1 US 20110020451 A1 US20110020451 A1 US 20110020451A1 US 12840471 US12840471 US 12840471 US 84047110 A US84047110 A US 84047110A US 2011020451 A1 US2011020451 A1 US 2011020451A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
preferably
dosage
pharmaceutical
wt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US12840471
Inventor
Johannes Bartholomäus
Anja Geissler
Ulrike Bertram
Kornelia Grießmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grunenthal GmbH
Original Assignee
Grunenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Abstract

Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising
    • an opioid (A),
    • a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and
    • a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

Description

  • [0001]
    The invention relates to a pharmaceutical dosage form which contains an opioid with improved storage stability.
  • [0002]
    Many pharmacologically active compounds have a potential of being abused and thus, are advantageously provided in form of tamper resistant pharmaceutical dosage forms. Prominent examples of such pharmacologically active compounds are opioids.
  • [0003]
    It is known that abusers crush conventional tablets, which contain opioids, to defeat the time-release “micro-encapsulation” and then ingest the resulting powder orally, intra-nasally, rectally, or by injection.
  • [0004]
    Various concepts for the avoidance of drug abuse have been developed. One concept relies on the mechanical properties of the pharmaceutical dosage forms, particularly an increased breaking strength (resistance to crushing). The major advantage of such pharmaceutical dosage forms is that comminuting, particularly pulverization, by conventional means, such as grinding in a mortar or fracturing by means of a hammer, is impossible or at least substantially impeded.
  • [0005]
    Such pharmaceutical dosage forms are useful for avoiding drug abuse of the pharmacologically active compound contained therein, as they may not be powdered by conventional means and thus, cannot be administered in powdered from, e.g. nasally. The mechanical properties, particularly the high breaking strength of these pharmaceutical dosage forms renders them tamper resistant. In the context of such tamper resistant pharmaceutical dosage forms it can be referred to, e.g., WO 2005/016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO 2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, WO 2006/082099, and WO 2008/107149.
  • [0006]
    A problem in the manufacture of pharmaceutical dosage forms that contain opioids, such as oxymorphone, hydromorphone, and oxycodone, is their sensitivity towards oxidative degradation and decomposition. Oxidation may be caused by molecular oxygen or by radicals or peroxides generated by compounds that come into close proximity with these oxidation-sensitive opioids. Pharmaceutical excipients as such, e.g. polyethylene glycols, may cause or catalyze oxidative degradation, for example in the course of the process for the manufacture the pharmaceutical dosage forms. Further, molecular oxygen may generate said radicals or peroxides.
  • [0007]
    Typically, decomposition is monitored in standard storage stability tests e.g. under accelerated storage conditions, such as 40° C./75% rel. humidity. Under these conditions, degradation and decomposition proceeds faster than under ambient conditions. The drug approving authorities, such as CHMP and FDA, and international harmonization unions, such as ICH, have set standard storage stability thresholds which have to be met in order to get a pharmaceutical dosage form approved.
  • [0008]
    Particular problems arise when the oxidation-sensitive opioid needs to be exposed to elevated temperatures in the course of the manufacturing process, such as hot-melt extrusion, film coating and the like. Under these conditions the opioids are even more sensitive towards oxidation. For example, several known processes for the manufacture of pharmaceutical dosage forms having an increased breaking strength require that a pharmaceutical composition containing the active ingredient is subjected to a specific amount of pressure at a specific elevated temperature for a specific period of time. Depending on the constituents of the pharmaceutical composition and their amounts, temperature, pressure and time may be varied within certain limits. However, if the minimal requirements are not satisfied, the breaking strength of the resultant pharmaceutical dosage form is too low.
  • [0009]
    In consequence, some conventional processes for the manufacture of pharmaceutical dosage forms, particularly for pharmaceutical dosage forms having an increased breaking strength, require comparatively harsh process conditions and thus, are so far not applicable for oxidation-sensitive opioids. In particular, chain rupture of pharmaceutical excipients such as polyethylene oxide during hot melt extrusion risks the formation of free radicals thereby further increasing the oxidative stress.
  • [0010]
    Lower dosages of oxidation-sensitive opioids often show a higher percentage of oxidative degradation and decomposition than higher dosages. Thus, as far as storage stability is concerned, pharmaceutical dosage forms containing lower dosages of oxidation-sensitive opioids need particular attention.
  • [0011]
    The effect of oxidation mechanisms and chemical interactions on stability of polymeric systems for amorphous A9-tetrahydrocannabinol (a non-opioid) produced by a hot-melt method is described in M. Munjal et al., J. Pharm. Sciences, 95(11), 2006, 2473-85. The study demonstrated for this highly unstable drug a complex nature of interactions including drug-excipient compatibility, use of antioxidants, cross-linking in polymeric matrixes, micro environment pH, and moisture effect.
  • [0012]
    K. C. Waterman et al., Pharm. Develop. Tech. 7(1), 2002, 1-32 reviews the stabilization of pharmaceuticals to oxidative degradation. Various methods for reducing oxidation are recommended. The authors conclude that in the end, every drug presents a unique situation.
  • [0013]
    WO 2008/107149 discloses oral dosage forms having an increased breaking strength that may contain redox stabilizers such as complexing agents, e.g. EDTA.
  • [0014]
    WO 2008/086804 relates to controlled release compositions containing a matrix composition comprising a) polymer or a mixture of polymers, b) an active drug substance and optionally c) one or more pharmaceutically acceptable excipients that is without alcohol induced dose dumping and have excellent properties with respect to avoiding drug abuse. Preferably, the composition is resistant to isolate and/or dissolve the active drug substance from the composition by crushing, melting and/or ethanol extraction, whereby the composition is resistant to drug abuse. Citric acid may be present as flavouring agent. Example 2 relates to a composition containing 7 wt.-% of citric acid.
  • [0015]
    WO 2008/148798 discloses an layered extended release composition for prolonged effect and a way to ensure prolonged effect e.g. once daily administration is to ensure optimal absorption of the active substance though the gastrointestinal tract i.e. from the stomach to rectum.
  • [0016]
    There is no general concept to successfully suppress oxidative degradation of oxidation-sensitive drugs in pharmaceutical dosage forms. The complex individual oxidation mechanisms that are relevant for a particular drug as well as the plurality of possible factors that have an influence on oxidation processes require extensive investigations in each particular case taking into account the particular circumstances.
  • [0017]
    It is further known that the other ingredients of the pharmaceutical dosage forms may show stability problems when being exposed to such harsh process conditions. For example, high molecular weight polyethylene oxide tends to degrade upon hot-melt extrusion. Polymer degradation, however, may result in an uncontrolled release profile, particularly when the active ingredient is embedded in a matrix of the polyethylene oxide, and this might be another cause for oxidative degradation of the active ingredient by radicals. When adding suitable excipients in order to stabilize the high molecular weight polyethylene oxide, such as α-tocopherol, it should be taken into considerations that said excipients in turn may have a detrimental effect on the stability of other ingredients of the pharmaceutical dosage, e.g. of the pharmacologically active compound.
  • [0018]
    It is an object of the present invention to provide tamper-resistant pharmaceutical dosage forms containing opioids, particularly oxidation-sensitive opioids, that have advantages over the pharmaceutical dosage forms of the prior art. The pharmaceutical dosage forms should have improved storage stability, so that they may contain oxidation-sensitive opioids even at comparatively low doses. Further, it should be possible to prepare the pharmaceutical dosage forms by conventional processes under conventional conditions such as elevated temperature and pressure (e.g. in the course of thermoforming by hot-melt extrusion).
  • [0019]
    This object has been solved by the subject-matter of the patent claims.
  • [0020]
    The invention relates to a thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N and comprising
      • an opioid (A),
      • a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and
      • a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
  • [0024]
    It has been surprisingly found that certain morphinan derivatives such as oxymorphone are oxidatively degraded to N-oxides (e.g., oxymorphone-N-oxide, N-oxides in general are often said to be toxic and possibly cancerogenic) upon manufacture and storage of the corresponding dosage forms and that the formation of said N-oxides and other decomposition products can be suppressed by the presence of suitable amounts of acid (B) in the pharmaceutical dosage forms according to the invention.
  • [0025]
    While it is not intended to be bound to any theory, the stabilizing effect of acid (B) might correlate with the pKA-value of the oxidation-sensitive opioids. The pKA-value of oxymorphone is 8.3. Conventional formulations of oxymorphone, which are tamper resistant due to their increased breaking strength but which do not show the desired shelf life, give a pH value of about 7.5 when being dispersed in water. Under these conditions, a considerable amount of the oxymorphone is present as a free base (i.e., is not protonated), which might be more sensitive towards oxidation than the (protonated) salt form. This concept is further supported by the fact that in the absence of acid (B), the dosage forms tend to have a yellowish, beige color, while the presence of acid (B) leads to whiter, e.g. colorless tablets. Thus, the presence of acid (B) might decrease the pH value within the dosage form thereby improving drug resistance towards oxidative degradation.
  • [0026]
    It has been surprisingly found that pharmaceutical excipients which are conventionally used in order to improve drug resistance towards oxidative degradation, particularly certain anti-oxidants, e.g., α-tocopherol, can be contra-productive and rather deteriorate than improve drug resistance towards oxidative degradation.
  • [0027]
    The pharmaceutical dosage form according to the invention is thermoformed, preferably by extrusion, although also other methods of thermoforming may be used in order to manufacture the pharmaceutical dosage form according to the invention such as press-molding at elevated temperature or heating of tablets that were manufactured by conventional compression in a first step and then heated above the softening temperature of the polymer in the tablet in a second step to form hard tablets. In this regards, thermoforming means the forming, or molding of a mass after the application of heat. In a preferred embodiment, the pharmaceutical dosage form is thermoformed by hot-melt extrusion.
  • [0028]
    Preferably, the pharmaceutical dosage form is a monolithic mass. The pharmaceutical dosage form is preferably prepared by hot-melt extrusion. The melt extruded strands are preferably cut into monoliths, which are then preferably formed into tablets. In this regard, the term “tablets” is preferably not to be understood as dosage forms being made by compression of powder or granules (compressi) but rather, as shaped extrudates.
  • [0029]
    The pharmaceutical dosage form according to the invention contains, as component (A), an opioid (A), preferably an oxidation-sensitive opioid (A), most preferably oxymorphone or oxycodone. For the purpose of the specification, the term opioid (A) also includes the free base and the physiologically acceptable salts thereof.
  • [0030]
    According to the ATC index, opioids are divided into natural opium alkaloids, phenylpiperidine derivatives, diphenylpropylamine derivatives, benzomorphan derivatives, oripavine derivatives, morphinan derivatives and others. Examples of natural opium alkaloids are morphine, opium, hydromorphone, nicomorphine, oxycodone, dihydrocodeine, diamorphine, papaveretum, and codeine. Further opioids (A) are, for example, ethylmorphine, hydrocodone, oxymorphone, and the physiologically acceptable derivatives thereof or compounds, preferably the salts and solvates thereof, preferably the hydrochlorides thereof, physiologically acceptable enantiomers, stereoisomers, diastereomers and racemates and the physiologically acceptable derivatives thereof, preferably ethers, esters or amides.
  • [0031]
    Further preferred opioids (A) include N-(1-methyl-2-piperidinoethyl)-N-(2-pyridyl)propionamide, (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol, (1R,2R,4S)-2-(dimethyl-amino)methyl-4-(p-fluorobenzyloxy)-1-(m-methoxyphenyl)cyclohexanol, (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)phenol, (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol, (2R,3R)-1-dimethylannino-3(3-methoxyphenyl)-2-methyl-pentan-3-ol, (1RS,3RS-6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, preferably as racemate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 2-(4-isobutyl-phenyl)propionate, 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(4-isobutyl-phenyl)propionate, 3-(2-dimethylaminomethyl-cyclohex-1-enyl)-phenyl 2-(6-methoxy-naphthalen-2-yl)-propionate, (RR—SS)-2-acetoxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-trifluoromethyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-4-chloro-2-hydroxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methyl-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-4-methoxy-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2-hydroxy-5-nitro-benzoic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, (RR—SS)-2′,4′-difluoro-3-hydroxy-biphenyl-4-carboxylic acid 3-(2-dimethylaminomethyl-1-hydroxy-cyclohexyl)-phenyl ester, 1,1-(3-dimethylamino-3-phenyl-pentamethylene)-6-fluor-1,3,4,9-tetrahydropyrano[3,4-b]indole, in particular its hemicitrate; 1,1-[3-dimethylannino-3-(2-thienyl)pentamethylen]-1,3,4,9-tetrahydropyrano[3,4-b]indole, in particular its citrate; and 1,1-[3-dimethylamino-3-(2-thienyl)pentamethylen]-1,3,4,9-tetra-hydropyrano[3,4-b]-6-fluoro-indole, in particular its hemicitrate, and corresponding stereo-isomeric compounds, in each case the corresponding derivatives thereof, physiologically acceptable enantiomers, stereoisomers, diastereomers and racemates and the physiologically acceptable derivatives thereof, e.g. ethers, esters or amides, and in each case the physiologically acceptable compounds thereof, in particular the salts thereof and solvates, e.g. hydrochlorides.
  • [0032]
    Preferred opioids (A) are of general formula (I)
  • [0000]
    Figure US20110020451A1-20110127-C00001
  • [0033]
    wherein
      • R1 is —H, —OH or —OC1-6-alkyl;
      • R2 is —H or —C1-6-alkyl;
      • R3 is —H or —OH and R4 is —H; or R3 and R4 together are ═O; and
      • —is an optional double bond;
  • [0038]
    or the physiologically acceptable salts thereof.
  • [0039]
    Particularly preferred opioids (A) include oxymorphone, oxycodone, hydromorphone, and the physiologically acceptable salts thereof.
  • [0040]
    The content of the opioid (A) in the pharmaceutical dosage form is not limited.
  • [0041]
    Preferably, its content is within the range of from 0.01 to 80 wt.-%, more preferably 0.1 to 50 wt.-%, still more preferably 1 to 25 wt.-%, based on the total weight of the pharmaceutical dosage form. In a preferred embodiment, the content of opioid (A) is within the range of from 7±6 wt.-%, more preferably 7±5 wt.-%, still more preferably 5±4 wt.-%, 7±4 wt.-% or 9±4 wt.-%, most preferably 5±3 wt.-%, 7±3 wt.-% or 9±3 wt.-%, and in particular 5±2 wt.-%, 7±2 wt.-% or 9±2 wt.-%, based on the total weight of the pharmaceutical dosage form. In another preferred embodiment, the content of opioid (A) is within the range of from 11±10 wt.-%, more preferably 11±9 wt.-%, still more preferably 9±6 wt.-%, 11±6 wt.-%, 13±6 wt.-% or 15±6 wt.-%, most preferably 11±4 wt.-%, 13±4 wt.-% or 15±4 wt.-%, and in particular 11±2 wt.-%, 13±2 wt.-% or 15±2 wt.-%, based on the total weight of the pharmaceutical dosage form. In a further preferred embodiment, the content of opioid (A) is within the range of from 20±6 wt.-%, more preferably 20±5 wt.-%, still more preferably 20±4 wt.-%, most preferably 20±3 wt.-%, and in particular 20±2 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0042]
    Preferably, the total amount of the opioid (A) that is contained in the pharmaceutical dosage form is within the range of from 0.01 to 200 mg, more preferably 0.1 to 190 mg, still more preferably 1.0 to 180 mg, yet more preferably 1.5 to 160 mg, most preferably 2.0 to 100 mg and in particular 2.5 to 80 mg.
  • [0043]
    In a preferred embodiment, the opioid (A) is contained in the pharmaceutical dosage form in an amount of 7.5±5 mg, 10±5 mg, 20±5 mg, 30±5 mg, 40±5 mg, 50±5 mg, 60±5 mg, 70±5 mg, 80±5 mg, 90±5 mg, 100±5 mg, 110±5 mg, 120±5 mg, 130±5, 140±5 mg, 150±5 mg, or 160±5 mg. In another preferred embodiment, the opioid (A) is contained in the pharmaceutical dosage form in an amount of 5±2.5 mg, 7.5±2.5 mg, 10±2.5 mg, 15±2.5 mg, 20±2.5 mg, 25±2.5 mg, 30±2.5 mg, 35±2.5 mg, 40±2.5 mg, 45±2.5 mg, 50±2.5 mg, 55±2.5 mg, 60±2.5 mg, 65±2.5 mg, 70±2.5 mg, 75±2.5 mg, 80±2.5 mg, 85±2.5 mg, 90±2.5 mg, 95±5 mg, 100±2.5 mg, 105±2.5 mg, 110±2.5 mg, 115±2.5 mg, 120±2.5 mg, 125±2.5 mg, 130±2.5 mg, 135±2.5 mg, 140±2.5 mg, 145±2.5 mg, 150±2.5 mg, 155±2.5 mg, or 160±2.5 mg.
  • [0044]
    In a particularly preferred embodiment, opioid (A) is oxymorphone, preferably its HCl salt, and the pharmaceutical dosage form is adapted for administration twice daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 5 to 40 mg. In another particularly preferred embodiment, opioid (A) is oxymorphone, preferably its HCl, and the pharmaceutical dosage form is adapted for administration once daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 10 to 80 mg.
  • [0045]
    In another particularly preferred embodiment, opioid (A) is oxycodone, preferably its HCl salt, and the pharmaceutical dosage form is adapted for administration twice daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 5 to 80 mg. In another particularly preferred embodiment, opioid (A) is oxycodone, preferably its HCl, and the pharmaceutical dosage form is adapted for administration once daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 10 to 320 mg.
  • [0046]
    In still another particularly preferred embodiment, opioid (A) is hydromorphone, preferably its HCl, and the pharmaceutical dosage form is adapted for administration twice daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 2 to 52 mg. In another particularly preferred embodiment, opioid (A) is hydromorphone, preferably its HCl, and the pharmaceutical dosage form is adapted for administration once daily. In this embodiment, opioid (A) is preferably contained in the pharmaceutical dosage form in an amount of from 4 to 104 mg.
  • [0047]
    The pharmaceutical dosage form according to the invention is characterized by excellent storage stability. Preferably, after storage for 4 weeks at 40° C. and 75% rel. humidity, the content of opioid (A) amounts to at least 98.0%, more preferably at least 98.5%, still more preferably at least 99.0%, yet more preferably at least 99.2%, most preferably at least 99.4% and in particular at least 99.6%, of its original content before storage. Suitable methods for measuring the content of the opioid (A) in the pharmaceutical dosage form are known to the skilled artisan. In this regard it is referred to the Eur. Ph. or the USP, especially to reversed phase HPLC analysis. Preferably, the pharmaceutical dosage form is stored in closed, preferably sealed containers, preferably as described in the experimental section, most preferably being equipped with an oxygen scavenger, in particular with an oxygen scavenger that is effective even at low relative humidity.
  • [0048]
    The pharmaceutical dosage form according to the invention contains, as component (B), a free physiologically acceptable acid in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form. The acid (B) may be organic or inorganic, liquid or solid. Solid acids are preferred, particularly crystalline organic or inorganic acids.
  • [0049]
    Acid (B) is free. This means that the acidic functional groups of the acid (B) are not all together constituents of a salt of the opioid (A). If the opioid (A) is present as a salt of an acid, e.g. as hydrochloride, the pharmaceutical dosage form according to the invention preferably contains as component (B) another, chemically different acid which is not present as a constituent of the salt of the opioid (A). In other words, monoacids that form a salt with opioid (A) are not to be considered as free acids (B) in the meaning of the present invention. When acid (B) has more than a single acidic functional group (e.g. phosphoric acid), the acid (B) may be present as a constituent of a salt of the opioid (A), provided that at least one of the acidic functional groups of the acid (B) is not involved in the formation of the salt, i.e. is free. Preferably, however, each and every acidic functional group of acid (B) is not involved in the formation of a salt with opioid (A). It is also possible, however, that free acid (B) and the acid forming a salt with opioid (A) are identical. Under these circumstances the acid (B) is preferably present in molar excess compared to opioid (A).
  • [0050]
    In a preferred embodiment, the acid (B) contains at least one acidic functional group (e.g. —CO2H, —S3H, —PO3H2, —OH and the like) having a pKA value within the range of 2.00±1.50, more preferably 2.00±1.25, still more preferably 2.00±1.00, yet more preferably 2.00±0.75, most preferably 2.00±0.50 and in particular 2.00±0.25. In another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 2.25±1.50, more preferably 2.25±1.25, still more preferably 2.25±1.00, yet more preferably 2.25±0.75, most preferably 2.25±0.50 and in particular 2.25±0.25. In another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 2.50±1.50, more preferably 2.50±1.25, still more preferably 2.50±1.00, yet more preferably 2.50±0.75, most preferably 2.50±0.50 and in particular 2.50±0.25. In another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 2.75±1.50, more preferably 2.75±1.25, still more preferably 2.75±1.00, yet more preferably 2.75±0.75, most preferably 2.75±0.50 and in particular 2.75±0.25. In another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 3.00±1.50, more preferably 3.00±1.25, still more preferably 3.00±1.00, yet more preferably 3.00±0.75, most preferably 3.00±0.50 and in particular 3.00±0.25. In still another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 3.25±1.50, more preferably 3.25±1.25, still more preferably 3.25±1.00, yet more preferably 3.25±0.75, most preferably 3.25±0.50 and in particular 3.25±0.25.
  • [0051]
    In yet another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 4.50±1.50, more preferably 4.50±1.25, still more preferably 4.50±1.00, yet more preferably 4.50±0.75, most preferably 4.50±0.50 and in particular 4.50±0.25. In yet another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 4.75±1.50, more preferably 4.75±1.25, still more preferably 4.75±1.00, yet more preferably 4.75±0.75, most preferably 4.75±0.50 and in particular 4.75±0.25. In yet another preferred embodiment, the acid (B) contains at least one acidic functional group having a pKA value within the range of 5.00±1.50, more preferably 5.00±1.25, still more preferably 5.00±1.00, yet more preferably 5.00±0.75, most preferably 5.00±0.50 and in particular 5.00±0.25.
  • [0052]
    Preferably, the acid (B) is an organic carboxylic or sulfonic acid, particularly a carboxylic acid. Multicarboxylic acids and/or hydroxy-carboxylic acids are especially preferred.
  • [0053]
    In case of multicarboxylic acids, the partial salts thereof are also to be regarded as multi-carboxylic acids, e.g. the partial sodium, potassium or ammonium salts. For example, citric acid is a multicarboxylic acid having three carboxyl groups. As long as there remains at least one carboxyl group protonated (e.g. sodium dihydrogen citrate or disodium hydrogen citrate), the salt is to be regarded as a multicarboxylic acid. Preferably, however, all carboxyl groups of the multicarboxylic acid are protonated.
  • [0054]
    Preferably, the acid (B) is of low molecular weight, i.e., not polymerized. Typically, the molecular weight of the acid (B) is below 500 g/mol.
  • [0055]
    Examples of acids include saturated and unsaturated monocarboxylic acids, saturated and unsaturated bicarboxylic acids, tricarboxylic acids, α-hydroxyacids and β-hydroxylacids of monocarboxylic acids, α-hydroxyacids and β-hydroxyacids of bicarboxylic acids, α-hydroxy-acids and β-hydroxyacids of tricarboxylic acids, ketoacids, α-ketoacids, β-ketoacids, of the polycarboxylic acids, of the polyhydroxy monocarboxylic acids, of the polyhydroxy bicarboxylic acids, of the polyhydroxy tricarboxylic acids.
  • [0056]
    Preferably, the acid (B) is selected from the group consisting of benzenesulfonic acid, citric acid, α-glucoheptonic acid, D-gluconic acid, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, propanoic acid, succinic acid, tartaric acid (d, I, or dI), tosic acid (toluene-sulfonic acid), valeric acid, palmitic acid, pamoic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, glutaric acid, 4-chlorobenzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, galactaric acid (mucic acid), D-glucuronic acid, 2-oxo-glutaric acid, glycerophosphoric acid, hippuric acid, isethionic acid (ethanolsulfonic acid), lactobionic acid, maleic acid, maleinic acid, 1,5-naphthalene-disulfonic acid, 2-naphthalene-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, cholic acid, n-dodecyl sulfate, 3-hydroxy-2-naphthoic acid, 1-hydroxy-2-naphthoic acid, oleic acid, undecylenic acid, ascorbic acid, (+)-camphoric acid, d-camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid, formic acid, methanesulfonic acid, nicotinic acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid, saccharine, salicylic acid, gentisic acid, and/or 4-acetamidobenzoic acid.
  • [0057]
    The content of the acid (B) is within the range of from 0.001 to 5.0 wt.-%, preferably 0.005 to 2.5 wt.-%, more preferably 0.01 to 2.0 wt.-%, still more preferably 0.05 to 1.5 wt.-%, most preferably 0.1 to 1.0 wt.-% and in particular 0.2 to 0.9 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0058]
    Preferably, the acid (B) is a multicarboxylic acid. More preferably, the multicarboxylic acid is selected from the group consisting of citric acid, maleic acid and fumaric acid.
  • [0059]
    Citric acid is particularly preferred.
  • [0060]
    The multicarboxylic acid, preferably citric acid, may be present in its anhydrous form or as a solvate and hydrate, respectively, e.g., as citric acid monohydrate.
  • [0061]
    In a preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.2±0.18 wt.-%, more preferably 0.2±0.15 wt.-%, still more preferably 0.2±0.12 wt.-%, yet more preferably 0.2±0.09 wt.-%, most preferably 0.2±0.06 wt.-%, and in particular 0.2±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0062]
    In another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.3±0.18 wt.-%, more preferably 0.3±0.15 wt.-%, still more preferably 0.3±0.12 wt.-%, yet more preferably 0.3±0.09 wt.-%, most preferably 0.3±0.06 wt.-%, and in particular 0.3±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0063]
    In still another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.4±0.18 wt.-%, more preferably 0.4±0.15 wt.-%, still more preferably 0.4±0.12 wt.-%, yet more preferably 0.4±0.09 wt.-%, most preferably 0.4±0.06 wt.-%, and in particular 0.4±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0064]
    In yet another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.5±0.18 wt.-%, more preferably 0.5±0.15 wt.-%, still more preferably 0.5±0.12 wt.-%, yet more preferably 0.5±0.09 wt.-%, most preferably 0.5±0.06 wt.-%, and in particular 0.5±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0065]
    In yet another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.6±0.18 wt.-%, more preferably 0.6±0.15 wt.-%, still more preferably 0.6±0.12 wt.-%, yet more preferably 0.6±0.09 wt.-%, most preferably 0.6±0.06 wt.-%, and in particular 0.6±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0066]
    In yet another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.7±0.18 wt.-%, more preferably 0.7±0.15 wt.-%, still more preferably 0.7±0.12 wt.-%, yet more preferably 0.7±0.09 wt.-%, most preferably 0.7±0.06 wt.-%, and in particular 0.7±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0067]
    In yet another preferred embodiment, the content of citric acid is within the range of 0.8±0.18 wt.-%, more preferably 0.8±0.15 wt.-%, still more preferably 0.8±0.12 wt.-%, yet more preferably 0.8±0.09 wt.-%, most preferably 0.8±0.06 wt.-%, and in particular 0.8±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0068]
    In yet another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.85±0.18 wt.-%, more preferably 0.85±0.15 wt.-%, still more preferably 0.85±0.12 wt.-%, yet more preferably 0.85±0.09 wt.-%, most preferably 0.85±0.06 wt.-%, and in particular 0.85±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0069]
    In still another preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 0.9±0.18 wt.-%, more preferably 0.9±0.15 wt.-%, still more preferably 0.9±0.12 wt.-%, yet more preferably 0.9±0.09 wt.-%, most preferably 0.9±0.06 wt.-%, and in particular 0.9±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0070]
    In a further preferred embodiment, the content of the acid (B), preferably citric acid is within the range of 1.0±0.18 wt.-%, more preferably 1.0±0.15 wt.-%, still more preferably 1.0±0.12 wt.-%, yet more preferably 1.0±0.09 wt.-%, most preferably 1.0±0.06 wt.-%, and in particular 1.0±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0071]
    The pharmaceutical dosage form according to the invention comprises, as component (C), a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol, preferably at least 500,000 g/mol, more preferably at least 750,000 g/mol, still more preferably at least 1,000,000 g/mol, most preferably at least 2,000,000 g/mol and in particular within the range of from 500,000 to 15,000,000 g/mol.
  • [0072]
    Preferably, the polyalkylene oxide is selected from the group consisting of polymethylene oxide, polyethylene oxide and polypropylene oxide, the copolymers and mixtures thereof.
  • [0073]
    Polyalkylene oxide (C) may comprise a single polyalkylene oxide having a particular average molecular weight, or a mixture (blend) of different polymers, such as two, three, four or five polymers, e.g., polymers of the same chemical nature but different average molecular weight, polymers of different chemical nature but same average molecular weight, or polymers of different chemical nature as well as different molecular weight.
  • [0074]
    For the purpose of the specification, a polyalkylene glycol has a molecular weight of up to 20,000 g/mol whereas a polyalkylene oxide has a molecular weight of more than 20,000 g/mol. In a preferred embodiment, the weight average over all molecular weights of all polyalkylene oxides that are contained in the pharmaceutical dosage form is at least 200,000 g/mol. Thus, polyalkylene glycols, if any, are preferably not taken into consideration when determining the weight average molecular weight of polyalkylene oxide (C).
  • [0075]
    Preferably, the content of the polyalkylene oxide (C) is within the range of from 20 to 99 wt.-%, more preferably 25 to 95 wt.-%, still more preferably 30 to 90 wt.-%, yet more preferably 30 to 85 wt.-%, most preferably 30 to 80 wt.-% and in particular 30 to 75 wt.-%, based on the total weight of the pharmaceutical dosage form. In a preferred embodiment, the content of the polyalkylene oxide is at least 20 wt.-%, more preferably at least 25 wt.-%, still more preferably at least 30 wt.-%, yet more preferably at least 35 wt.-% and in particular at least 40 wt.-%.
  • [0076]
    In a preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 25±20 wt.-%, more preferably 25±15 wt.-%, most preferably 25±10 wt.-%, and in particular 25±5 wt.-%. In another preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 35±20 wt.-%, more preferably 35±15 wt.-%, most preferably 35±10 wt.-%, and in particular 35±5 wt.-%. In still another preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 45±20 wt.-%, more preferably 45±15 wt.-%, most preferably 45±10 wt.-%, and in particular 45±5 wt.-%. In yet another preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 55±20 wt.-%, more preferably 55±15 wt.-%, most preferably 55±10 wt.-%, and in particular 55±5 wt.-%. In a further preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 65±20 wt.-%, more preferably 65±15 wt.-%, most preferably 65±10 wt.-%, and in particular 65±5 wt.-%. In still a further a preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 75±20 wt.-%, more preferably 75±15 wt.-%, most preferably 75±10 wt.-%, and in particular 75±5 wt.-%. In a still further a preferred embodiment, the overall content of polyalkylene oxide (C) is within the range of 80±15 wt.-%, more preferably 80±10 wt.-%, and most preferably 80±5 wt.-%.
  • [0077]
    In a preferred embodiment, polyalkylene oxide (C) is homogeneously distributed in the pharmaceutical dosage form according to the invention. Preferably, polyalkylene oxide (C) forms a matrix in which the opioid (A) is embedded. In a particularly preferred embodiment, the opioid (A) and polyalkylene oxide (C) are intimately homogeneously distributed in the pharmaceutical dosage form so that the pharmaceutical dosage form does not contain any segments where either opioid (A) is present in the absence of polyalkylene oxide (C) or where polyalkylene oxide (C) is present in the absence of opioid (A).
  • [0078]
    When the pharmaceutical dosage form is film coated, the polyalkylene oxide (C) is preferably homogeneously distributed in the core of the pharmaceutical dosage form, i.e. the film coating preferably does not contain polyalkylene oxide (C). Nonetheless, the film coating as such may of course contain one or more polymers, which however, preferably differ from the polyalkylene oxide (C) contained in the core.
  • [0079]
    The polyalkylene oxide (C) may be combined with one or more different polymers selected from the group consisting of polyalkylene oxide, preferably polymethylene oxide, polyethylene oxide, polypropylene oxide; polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyvinylpyrrolidone, poly(alk)acrylate, poly(hydroxy fatty acids), such as for example poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (Biopol®), poly(hydroxyvaleric acid); polycaprolactone, polyvinyl alcohol, polyesteramide, polyethylene succinate, polylactone, polyglycolide, polyurethane, polyamide, polylactide, polyacetal (for example polysaccharides optionally with modified side chains), polylactide/glycolide, polylactone, polyglycolide, polyorthoester, polyanhydride, block polymers of polyethylene glycol and polybutylene terephthalate (Polyactive®), polyanhydride (Polifeprosan), copolymers thereof, block-copolymers thereof, and mixtures of at least two of the stated polymers, or other polymers with the above characteristics.
  • [0080]
    Preferably, the molecular weight dispersity Mw/Mn of polyalkylene oxide (C) is within the range of 2.5±2.0, more preferably 2.5±1.5, still more preferably 2.5±1.0, yet more preferably 2.5±0.8, most preferably 2.5±0.6, and in particular 2.5±0.4.
  • [0081]
    The polyalkylene oxide (C) preferably has a viscosity at 25° C. of 30 to 17,600 cP, more preferably 55 to 17,600 cP, still more preferably 600 to 17,600 cP and most preferably 4,500 to 17,600 cP, measured in a 5 wt.-% aqueous solution using a model RVF Brookfield viscosimeter (spindle no. 2/rotational speed 2 rpm); of 400 to 4,000 cP, more preferably 400 to 800 cP or 2,000 to 4,000 cP, measured on a 2 wt.-% aqueous solution using the stated viscosimeter (spindle no. 1 or 3/rotational speed 10 rpm); or of 1,650 to 10,000 cP, more preferably 1,650 to 5,500 cP, 5,500 to 7,500 cP or 7,500 to 10,000 cP, measured on a 1 wt.-% aqueous solution using the stated viscosimeter (spindle no. 2/rotational speed 2 rpm).
  • [0082]
    In a preferred embodiment according to the invention the polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol is combined with at least one further polymer, preferably but not necessarily also having a weight average molecular weight (Mw) of at least 200,000 g/mol, selected from the group consisting of polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyacrylate, poly(hydroxy fatty acids), polycaprolactone, polyvinyl alcohol, polyesteramide, polyethylene succinate, polylactone, polyglycolide, polyurethane, polyvinylpyrrolidone, polyamide, polylactide, polylactide/glycolide, polylactone, polyglycolide, polyorthoester, polyanhydride, block polymers of polyethylene glycol and polybutylene terephthalate, polyanhydride, polyacetal, cellulose esters, cellulose ethers and copolymers thereof. Cellulose esters and cellulose ethers are particularly preferred, e.g. methylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxy-ethylcellulose, hydroxypropylcellulose hydroxypropylmethylcellulose, carboxymethylcellulose, and the like.
  • [0083]
    In a preferred embodiment, said further polymer is neither a polyalkylene oxide nor a poly-alkylene glycol. Nonetheless, the pharmaceutical dosage form may contain polyalkylene glycol, e.g. as plasticizer, but then, the pharmaceutical dosage form preferably is a ternary mixture of polymers: polyalkylene oxide (C)+further polymer+plasticizer.
  • [0084]
    In a particularly preferred embodiment, said further polymer is a hydrophilic cellulose ester or cellulose ether, preferably hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC) or hydroxyethylcellulose (HEC), preferably having an average viscosity (preferably measured by capillary viscosimetry or rotational viscosimetry) of 1,000 to 150,000 mPas, more preferably 3,000 to 150,000. In a preferred embodiment, the average viscosity is within the range of 110,000±50,000 mPas, more preferably 110,000±40,000 mPas, still more preferably 110,000±30,000 mPas, most preferably 110,000±20,000 mPas, and in particular 100,000±10,000 mPas.
  • [0085]
    In a preferred embodiment the relative weight ratio of said polyalkylene oxide (C) and said further polymer is within the range of from 20:1 to 1:20, more preferably 10:1 to 1:10, still more preferably 7:1 to 1:5, yet more preferably 5:1 to 1:1, most preferably 4:1 to 1,5:1 and in particular 3:1 to 2:1. In a preferred embodiment, the relative weight ratio of said polyalkylene oxide (C) and said further polymer is within the range of from 10:1 to 5:1, more preferably 8:1 to 5:1, most preferably 7:1 to 5:1.
  • [0086]
    Preferably, the content of said further polymer amounts to 0.5 to 25 wt.-%, more preferably 1.0 to 20 wt.-%, still more preferably 2.0 to 22.5 wt.-%, yet more preferably 3.0 to 20 wt.-% and most preferably 4.0 to 17.5 wt.-% and in particular 5.0 to 15 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0087]
    In a preferred embodiment, the further polymer is a cellulose ester or cellulose ether, preferably HPMC, having a content within the range of 10±8 wt.-%, more preferably 10±6 wt.-%, still more preferably 10±5 wt.-%, yet more preferably 10±4 wt.-%, most preferably 10±3 wt.-%, and in particular 10±2 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0088]
    In another preferred embodiment, the further polymer is a cellulose ester or cellulose ether, preferably HPMC, having a content within the range of 14±8 wt.-%, more preferably 14±6 wt.-%, still more preferably 14±5 wt.-%, yet more preferably 14±4 wt.-%, most preferably 14±3 wt.-%, and in particular 14±2 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0089]
    All polymers are preferably employed as powders. They can be soluble in water.
  • [0090]
    Besides the opioid (A), the acid (B) and polyalkylene oxide (C) the pharmaceutical dosage form according to the invention may contain further constituents, such as conventional pharmaceutical excipients.
  • [0091]
    Preferably, the pharmaceutical dosage form comprises an antioxidant. Suitable antioxidants include ascorbic acid, α-tocopherol (vitamin E), butylhydroxyanisol, butylhydroxytoluene, salts of ascorbic acid (vitamin C), ascorbylic palmitate, monothioglycerine, coniferyl benzoate, nordihydroguajaretic acid, gallus acid esters, phosphoric acid, and the derivatives thereof, such as vitamin E-succinate or vitamin E-palmitate and/or sodium bisulphite, more preferably butylhydroxytoluene (BHT) or butylhydroxyanisol (BHA) and/or α-tocopherol.
  • [0092]
    Preferably, the content of the antioxidant is within the range of from 0.001 to 5.0 wt.-%, more preferably 0.002 to 2.5 wt.-%, more preferably 0.003 to 1.5 wt.-%, still more preferably 0.005 to 1.0 wt.-%, yet more preferably 0.01 to 0.5 wt.-%, most preferably 0.05 to 0.4 wt.-% and in particular 0.1 to 0.3 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0093]
    A particularly preferred antioxidant is α-tocopherol. It has been surprisingly found that α-tocopherol stabilizes polyalkylene oxide and simultaneously destabilizes certain opioids (A), such as oxymorphone. Thus, in a preferred embodiment, the content of α-tocopherol is balanced between a sufficient stability of the polyalkylene oxide on the one hand and a sufficient stability of the opioid (A) on the other hand.
  • [0094]
    In a preferred embodiment, the content of α-tocopherol is within the range of 0.2±0.18 wt.-%, more preferably 0.2±0.15 wt.-%, still more preferably 0.2±0.12 wt.-%, yet more preferably 0.2±0.09 wt.-%, most preferably 0.2±0.06 wt.-%, and in particular 0.2±0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0095]
    In a preferred embodiment, the relative weight ratio of the acid (B), preferably citric acid, and the antioxidant, preferably α-tocopherol, is within the range of from 10:1 to 1:10, more preferably 8:1 to 1:8, still more preferably 6:1 to 1:6, yet more preferably 5:1 to 1:4, most preferably 4:1 to 1:3 and in particular 3:1 to 1:2.
  • [0096]
    The pharmaceutical dosage form according to the invention may also contain a natural, semi-synthetic or synthetic wax. Waxes with a softening point of at least 50° C., more preferably 60° C. are preferred. Carnauba wax and beeswax are particularly preferred, especially carnauba wax.
  • [0097]
    Preferably, the release profile of the opioid (A) is matrix-retarded. Preferably, the opioid (A) is embedded in a matrix comprising the polyalkylene oxide, said matrix controlling the release of the opioid (A) from the pharmaceutical dosage form.
  • [0098]
    Physiologically acceptable materials which are known to the person skilled in the art may be used as supplementary matrix materials. Polymers, particularly preferably cellulose ethers, cellulose esters and/or acrylic resins are preferably used as hydrophilic matrix materials. Ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, poly(meth)acrylic acid and/or the derivatives thereof, such as the salts, amides or esters thereof are very particularly preferably used as matrix materials.
  • [0099]
    Matrix materials prepared from hydrophobic materials, such as hydrophobic polymers, waxes, fats, long-chain fatty acids, fatty alcohols or corresponding esters or ethers or mixtures thereof are also preferred. Mono- or diglycerides of C12-C30 fatty acids and/or C12-C30 fatty alcohols and/or waxes or mixtures thereof are particularly preferably used as hydrophobic materials. It is also possible to use mixtures of the above-stated hydrophilic and hydrophobic materials as matrix materials.
  • [0100]
    Preferably, the relative weight ratio of the polyalkylene oxide to the opioid (A) is at least 0.5:1, more preferably at least 1:1, at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least 6:1, at least 7:1, at least 8:1 or at least 9:1; still more preferably at least 10:1 or at least 15:1, yet more preferably at least 20:1, most preferably at least 30:1 and in particular at least 40:1. In a preferred embodiment, the relative weight ratio of the polyalkylene oxide to the opioid (A) is within the range of from 3:1 to 50:1, more preferably 3:1 to 40:1 and in particular 3:1 to 30:1.
  • [0101]
    The pharmaceutical dosage form according to the invention preferably contains a plasticizer. The plasticizer improves the processability of the polyalkylene oxide. A preferred plasticizer is polyalkylene glycol, like polyethylene glycol, triacetin, fatty acids, fatty acid esters, waxes and/or microcrystalline waxes. Particularly preferred plasticizers are polyethylene glycols, such as PEG 6000.
  • [0102]
    Preferably, the content of the plasticizer is within the range of from 0.1 to 25 wt.-%, more preferably 0.5 to 22.5 wt.-%, still more preferably 1.0 to 20 wt.-%, yet more preferably 2.5 to 17.5 wt.-%, most preferably 5.0 to 15 wt.-% and in particular 7.5 to 12.5 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0103]
    In a preferred embodiment, the plasticizer is a polyalkylene glycol having a content within the range of 10±8 wt.-%, more preferably 10±6 wt.-%, still more preferably 10±5 wt.-%, yet more preferably 10±4 wt.-%, most preferably 10±3 wt.-%, and in particular 10±2 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0104]
    In another preferred embodiment, the plasticizer is a polyalkylene glycol having a content within the range of 15±8 wt.-%, more preferably 15±6 wt.-%, still more preferably 15±5 wt.-%, yet more preferably 15±4 wt.-%, most preferably 15±3 wt.-%, and in particular 15±2 wt.-%, based on the total weight of the pharmaceutical dosage form.
  • [0105]
    In a preferred embodiment, the relative weight ratio of the polyalkylene oxide to the polyalkylene glycol is within the range of 4.2±2:1, more preferably 4.2±1.5:1, still more preferably 4.2±1:1, yet more preferably 4.2±0.5:1, most preferably 4.2±0.2:1, and in particular 4.2±0.1:1. This ratio satisfies the requirements of relative high polyalkylene oxide content and good extrudability.
  • [0106]
    When manufacturing the dosage forms from slices that are obtained by cutting the extrudate strand, the weight of the slices determines the weight of the resulting dosage form. Pronounced variation in weight of these slices results in an accordant weight deviation of dosage forms from the target weight. The weight variation of slices depends strongly on the surface properties of the extrudate strand. A strand with a thoroughly smooth surface allows the generation of slices exhibiting a low weight variation. In contrast, a wavy or shark skinning strand results in slices exhibiting a higher weight variation thereby increasing the number of rejects.
  • [0107]
    It has now been surprisingly found that the surface properties of the extrudate strand can be triggered by the polyalkylene oxide:polyalkylene glycol weight ratio.
  • [0108]
    Preferred compositions X1 to X32 of the pharmaceutical dosage form according to the invention are summarized in the tables here below:
  • [0000]
    wt.-% X1 X2 X3 X4
    opioid (A) (e.g. oxymorphone HCl) 1.50 ± 1.25 1.50 ± 1.00 1.50 ± 0.75 1.50 ± 0.50 
    acid (B) (e.g. citric acid)  0.5 ± 0.30  0.5 ± 0.25  0.5 ± 0.20  0.5 ± 0.15
    polyalkylene oxide (C) 77 ± 22 77 ± 20 77 ± 15 77 ± 10 
    cellulose ester or ether (e.g. HPMC) 12 ± 10  12 ± 7.5 12 ± 5  12 ± 2.5
    plasticizer (e.g. PEG)  10 ± 7.5 10 ± 5   10 ± 2.5 10 ± 1.0
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X5 X6 X7 X8
    opioid (A) (e.g. oxymorphone HCl) 2.33 ± 1.25 2.33 ± 1.00 2.33 ± 0.75 2.33 ± 0.50
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50 0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 70 ± 25 70 ± 20 70 ± 15 70 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5   10 ± 2.5
    plasticizer (e.g. PEG) 16.6 ± 7.5  16.6 ± 5   16.6 ± 2.5  16.6 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X9 X10 X11 X12
    opioid (A) (e.g. oxymorphone HCl) 3.50 ± 1.25 3.50 ± 1.00 3.50 ± 0.75 3.50 ± 0.50
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50 0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 69 ± 30 69 ± 20 69 ± 15 69 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5   10 ± 2.5
    plasticizer (e.g. PEG) 16.4 ± 7.5  16.4 ± 5   16.4 ± 2.5  16.4 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X13 X14 X15 X16
    opioid (A) (e.g. oxymorphone HCl) 4.65 ± 1.25 4.65 ± 1.00 4.65 ± 0.75 4.65 ± 0.50
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50 0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 68 ± 30 68 ± 20 68 ± 15 68 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5   10 ± 2.5
    plasticizer (e.g. PEG) 16.2 ± 7.5  16.2 ± 5   16.2 ± 2.5  16.2 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X17 X18 X19 X20
    opioid (A) (e.g. oxymorphone HCl) 6.98 ± 1.25 6.98 ± 1.00 6.98 ± 0.75 6.98 ± 0.50
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50 0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 66 ± 30 66 ± 20 66 ± 15 66 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5   10 ± 2.5
    plasticizer (e.g. PEG) 15.8 ± 7.5  15.8 ± 5   15.8 ± 2.5  15.8 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X21 X22 X23 X24
    opioid (A) (e.g. oxymorphone HCl) 9.30 ± 1.25 9.30 ± 1.00 9.30 ± 0.75 9.30 ± 0.50
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50 0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 64 ± 30 64 ± 20 64 ± 15 64 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5   10 ± 2.5
    plasticizer (e.g. PEG) 15.3 ± 7.5  15.3 ± 5   15.3 ± 2.5  15.3 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X25 X26 X27 X28
    opioid (A) (e.g. oxymorphone HCl) 13.95 ± 1.25  13.95 ± 1.00  13.95 ± 0.75 13.95 ± 0.50 
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50  0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 60 ± 30 60 ± 20  60 ± 15 60 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5  10 ± 2.5
    plasticizer (e.g. PEG) 13.9 ± 7.5  13.9 ± 5   13.9 ± 2.5 13.9 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0000]
    wt.-% X29 X30 X31 X32
    opioid (A) (e.g. oxymorphone HCl) 18.60 ± 1.25  18.60 ± 1.00  18.60 ± 0.75 18.60 ± 0.50 
    acid (B) (e.g. citric acid) 0.85 ± 0.60 0.85 ± 0.50  0.85 ± 0.25 0.85 ± 0.15
    polyalkylene oxide (C) 57 ± 30 57 ± 20  57 ± 15 57 ± 10
    cellulose ester or ether (e.g. HPMC)  10 ± 9.5  10 ± 7.5 10 ± 5  10 ± 2.5
    plasticizer (e.g. PEG) 13.6 ± 7.5  13.6 ± 5   13.6 ± 2.5 13.6 ± 1.0 
    antioxidant (e.g. α-tocopherol)  0.2 ± 0.12 0.2 ± 0.1  0.2 ± 0.05  0.2 ± 0.03
  • [0109]
    In a preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 100±75 mg, more preferably 100±50 mg, most preferably 100±25 mg. In another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 200±75 mg, more preferably 200±50 mg, most preferably 200±25 mg. In another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 250±75 mg, more preferably 250±50 mg, most preferably 250±25 mg. In still another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 300±75 mg, more preferably 300±50 mg, most preferably 300±25 mg. In yet another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 400±75 mg, more preferably 400±50 mg, most preferably 400±25 mg.
  • [0110]
    In a preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 500±250 mg, more preferably 500±200 mg, most preferably 500±150 mg. In another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 750±250 mg, more preferably 750±200 mg, most preferably 750±150 mg. In another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 1000±250 mg, more preferably 1000±200 mg, most preferably 1000±150 mg. In still another preferred embodiment, the pharmaceutical dosage form has a total weight within the range of 1250±250 mg, more preferably 1250±200 mg, most preferably 1250±150 mg.
  • [0111]
    In a preferred embodiment, the pharmaceutical dosage form according to the invention has an overall density within the range of 1.19±0.30 g/cm3, more preferably 1.19±0.25 g/cm3, still more preferably 1.19±0.20 g/cm3, yet more preferably 1.19±0.15 g/cm3, most preferably 1.19±0.10 g/cm3, and in particular 1.19±0.05 g/cm3. Preferably, the overall density of the pharmaceutical dosage form according to the invention is 1.17±0.02 g/cm3, 1.19±0.02 g/cm3 or 1.21±0.02 g/cm3. Methods for measuring the density of a dosage form are known to a person skilled in the art. The overall density of a dosage form can for example be determined by means of the mercury porosimetry method or the helium pycnometer method as described in Ph. Eur.
  • [0112]
    Preferably, the pharmaceutical dosage form according to the invention is adapted for oral administration. It is also possible, however, to administer the pharmaceutical dosage form via different routes and thus, the pharmaceutical dosage form may alternatively be adapted for buccal, lingual, rectal or vaginal administration. Implants are also possible.
  • [0113]
    In a preferred embodiment, the pharmaceutical dosage form according to the invention is adapted for administration once daily. In another preferred embodiment, the pharmaceutical dosage form according to the invention is adapted for administration twice daily. In still another preferred embodiment, the pharmaceutical dosage form according to the invention is adapted for administration thrice daily.
  • [0114]
    For the purpose of the specification, “twice daily” means equal or nearly equal time intervals, i.e., about every 12 hours, or different time intervals, e.g., 8 and 16 hours or 10 and 14 hours, between the individual administrations.
  • [0115]
    For the purpose of the specification, “thrice daily” means equal or nearly equal time intervals, i.e., about every 8 hours, or different time intervals, e.g., 6, 6 and 12 hours; or 7, 7 and 10 hours, between the individual administrations.
  • [0116]
    Preferably, the pharmaceutical dosage form according to the invention causes an at least partially delayed or prolonged release of opioid (A).
  • [0117]
    Controlled or prologned release is understood according to the invention preferably to mean a release profile in which the opioid (A) is released over a relatively long period with reduced intake frequency with the purpose of extended therapeutic action. Preferably, the meaning of the term “prolonged release” is in accordance with the European guideline on the nomenclature of the release profile of pharmaceutical dosage forms (CHMP). This is achieved in particular with peroral administration. The expression “at least partially delayed or prolonged release” covers according to the invention any pharmaceutical dosage forms which ensure modified release of the opioids (A) contained therein. The pharmaceutical dosage forms preferably comprise coated or uncoated pharmaceutical dosage forms, which are produced with specific auxiliary substances, by particular processes or by a combination of the two possible options in order purposefully to change the release rate or location of release.
  • [0118]
    In the case of the pharmaceutical dosage forms according to the invention, the release time profile of a controlled release form may be modified e.g. as follows: extended release, repeat action release, prolonged release and sustained release.
  • [0119]
    For the purpose of the specification “controlled release” preferably means a product in which the release of active compound over time is controlled by the type and composition of the formulation. For the purpose of the specification “extended release” preferably means a product in which the release of active compound is delayed for a finite lag time, after which release is unhindered. For the purpose of the specification “repeat action release” preferably means a product in which a first portion of active compound is released initially, followed by at least one further portion of active compound being released subsequently. For the purpose of the specification “prolonged release” preferably means a product in which the rate of release of active compound from the formulation after administration has been reduced over time, in order to maintain therapeutic activity, to reduce toxic effects, or for some other therapeutic purpose. For the purpose of the specification “sustained release” preferably means a way of formulating a medicine so that it is released into the body steadily, over a long period of time, thus reducing the dosing frequency. For further details, reference may be made, for example, to K. H. Bauer, Lehrbuch der Pharmazeutischen Technologie, 6th edition, WVG Stuttgart, 1999; and Eur. Ph.
  • [0120]
    The pharmaceutical dosage form according to the invention may comprise one or more opioids (A) at least in part in a further controlled release form, wherein controlled release may be achieved with the assistance of conventional materials and processes known to the person skilled in the art, for example by embedding the substance in a controlled release matrix or by applying one or more controlled release coatings. Substance release must, however, be controlled such that addition of delayed-release materials does not impair the necessary breaking strength. Controlled release from the pharmaceutical dosage form according to the invention is preferably achieved by embedding the substance in a matrix. Preferably, polyalkylene oxide (C) serves as such a matrix. The auxiliary substances acting as matrix materials control release. Matrix materials may, for example, be hydrophilic, gel-forming materials, from which release proceeds mainly by diffusion, or hydrophobic materials, from which release proceeds mainly by diffusion from the pores in the matrix.
  • [0121]
    Preferably, the release profile is substantially matrix controlled, preferably by embedding opioid (A) in a matrix comprising polyalkylene oxide (C) and optionally, further matrix materials. Preferably, the release profile is not osmotically driven. Preferably, release kinetics is not zero order.
  • [0122]
    Preferably, under physiological conditions the pharmaceutical dosage form according to the invention has released after 30 minutes 0.1 to 75%, after 240 minutes 0.5 to 95%, after 480 minutes 1.0 to 100% and after 720 minutes 2.5 to 100% of the opioid (A). Further preferred release profiles R1 to R6 are summarized in the table here below [all data in wt.-% of released opioid (A)]:
  • [0000]
    time R1 R2 R3 R4 R5 R6
    60 min 0-30 0-50 0-50 15-25 20-30 20-50
    120 min 0-40 0-75 0-75 25-40 35-50 40-75
    240 min 3-55 3-95 10-95  40-70 55-75 60-95
    480 min 10-65  10-100 35-100 60-90 80-95  80-100
    720 min 20-75  20-100 55-100  70-100  90-100  90-100
    960 min 30-88  30-100 70-100 >80  95-100
    1440 min 50-100 50-100 >90
    2160 min >80 >80
  • [0123]
    Further preferred release profiles R1 to R6 are summarized in the table here below [all data in wt.-% of released opioid (A)]:
  • [0000]
    time R7 R8 R9 R10 R11 R12
    30 min 17.5 ± 7.5 17.5 ± 6.5 17.5 ± 5.5 17.5 ± 4.5 17.5 ± 3.5 17.5 ± 2.5
    60 min 27.0 ± 8.0 27.0 ± 7.0 27.0 ± 6.0 27.0 ± 5.0 27.0 ± 4.0 27.0 ± 3.0
    120 min 41.5 ± 9.5 41.5 ± 8.5 41.5 ± 7.5 41.5 ± 6.5 41.5 ± 5.5 41.5 ± 4.5
    240 min  64.5 ± 12.5  64.5 ± 11.5  64.5 ± 10.5 64.5 ± 9.5 64.5 ± 8.5 64.5 ± 7.5
    480 min  88.0 ± 12.0  88.0 ± 11.0  88.0 ± 10.0 88.0 ± 9.0 88.0 ± 8.0 88.0 ± 7.0
    720 min 96.0 ± 9.0 96.0 ± 8.0 96.0 ± 7.0 96.0 ± 6.0 96.0 ± 5.0 96.0 ± 4.0
    840 min 97.5 ± 7.5 97.5 ± 6.5 97.5 ± 5.5 97.5 ± 4.5 97.5 ± 3.5 97.5 ± 2.5
  • [0124]
    Preferably, the release profile of the pharmaceutical dosage form according to the present invention is stable upon storage, preferably upon storage at elevated temperature, e.g. 37° C., for 3 months in sealed containers. In this regard “stable” means that when comparing the initial release profile with the release profile after storage, at any given time point the release profiles deviate from one another by not more than 20%, more preferably not more than 15%, still more preferably not more than 10%, yet more preferably not more than 7.5%, most preferably not more than 5.0% and in particular not more than 2.5%.
  • [0125]
    Preferably, under in vitro conditions the pharmaceutical dosage form has released after 0.5 h 1.0 to 35 wt.-%, after 1 h 5.0 to 45 wt.-%, after 2 h 10 to 60 wt.-%, after 4 h at least 15 wt-%, after 6 h at least 20 wt.-%, after 8 h at least 25 wt.-% and after 12 h at least 30 wt.-% of the opioid (A) that was originally contained in the pharmaceutical dosage form.
  • [0126]
    Suitable in vitro conditions are known to the skilled artisan. In this regard it can be referred to, e.g., the Eur. Ph. Preferably, the release profile is measured under the following conditions: Paddle apparatus equipped with sinker, 50 rpm, 37±5° C., 900 mL simulated intestinal fluid pH 6.8 (phosphate buffer) or pH 4.5. In a preferred embodiment, to rotational speed of the paddle is increased to 100 rpm.
  • [0127]
    In a preferred embodiment, after preferably oral administration of the pharmaceutical dosage form according to the invention, in vivo the average peak plasma level (Cmax) is on average reached after tmax 4.0±2.5 h, more preferably after tmax 4.0±2.0 h, still more preferably after tmax 4.0±1.5 h, most preferably after tmax 4.0±1.0 h and in particular after tmax 4.0±0.5 h. In another preferred embodiment, after preferably oral administration of the pharmaceutical dosage form according to the invention, in vivo the average peak plasma level (Cmax) is on average reached after tmax 5.0±2.5 h, more preferably after tmax 5.0±2.0 h, still more preferably after tmax 5.0±1.5 h, most preferably after tmax 5.0±1.0 h and in particular after tmax 5.0±0.5 h. In still another preferred embodiment, after preferably oral administration of the pharmaceutical dosage form according to the invention, in vivo the average peak plasma level (Cmax) is on average reached after tmax 6.0±2.5 h, more preferably after tmax 6.0±2.0 h, still more preferably after tmax 6.0±1.5 h, most preferably after tmax 6.0±1.0 h and in particular after tmax 6.0±0.5 h.
  • [0128]
    In a preferred embodiment, the average value for t1/2 after preferably oral administration of the pharmaceutical dosage form according to the invention in vivo is 4.0±2.5 h, more preferably 4.0±2.0 h, still more preferably 4.0±1.5 h, most preferably 4.0±1.0 h, and in particular 4.0±0.5 h. In another preferred embodiment, the average value for t1/2 after preferably oral administration of the pharmaceutical dosage form according to the invention in vivo is preferably 5.0±2.5 h, more preferably 5.0±2.0 h, still more preferably 5.0±1.5 h, most preferably 5.0±1.0 h, and in particular 5.0±0.5 h. In still another preferred embodiment, the average value for t1/2 after preferably oral administration of the pharmaceutical dosage form according to the invention in vivo is preferably 6.0±2.5 h, more preferably 6.0±2.0 h, still more preferably 6.0±1.5 h, most preferably 6.0±1.0 h, and in particular 6.0±0.5 h.
  • [0129]
    Preferably, the pharmaceutical dosage form according to the invention contains a coating, preferably a film-coating. Suitable coating materials are known to the skilled person. Suitable coating materials are commercially available, e.g. under the trademarks Opadry® and Eudragit®.
  • [0130]
    Examples of suitable materials include cellulose esters and cellulose ethers, such as methyl-cellulose (MC), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), sodium carboxymethylcellulose (Na-CMC), ethylcellulose (EC), cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose phthalate (HPMCP); poly(meth)acrylates, such as aminoalkylmethacrylate copolymers, ethylacrylate methyl-methacrylate copolymers, methacrylic acid methylmethacrylate copolymers, methacrylic acid methylmethacrylate copolymers; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl-acetatephthalate, polyvinyl alcohol, polyvinylacetate; and natural film formers, such as shellack.
  • [0131]
    In a particularly preferred embodiment, the coating is water-soluble. In a preferred embodiment, the coating is based on polyvinyl alcohol, such as polyvinyl alcohol-part. hydrolyzed, and may additionally contain polyethylene glycol, such as macrogol 3350, and/or pigments. In another preferred embodiment, the coating is based on hydroxypropylmethyl-cellulose, preferably hypromellose type 2910 having a viscosity of 3 to 15 mPas.
  • [0132]
    The coating of the pharmaceutical dosage form can increase its storage stability.
  • [0133]
    The coating can be resistant to gastric juices and dissolve as a function of the pH value of the release environment. By means of this coating, it is possible to ensure that the pharmaceutical dosage form according to the invention passes through the stomach undissolved and the active compound is only released in the intestines. The coating which is resistant to gastric juices preferably dissolves at a pH value of between 5 and 7.5. Corresponding materials and methods for the delayed release of active compounds and for the application of coatings which are resistant to gastric juices are known to the person skilled in the art, for example from “Coated Pharmaceutical dosage forms—Fundamentals, Manufacturing Techniques, Biopharmaceutical Aspects, Test Methods and Raw Materials” by Kurt H. Bauer, K. Lehmann, Hermann P. Osterwald, Rothgang, Gerhart, 1st edition, 1998, Medpharm Scientific Publishers.
  • [0134]
    In a preferred embodiment, the pharmaceutical dosage form according to the invention contains no substances which irritate the nasal passages and/or pharynx, i.e. substances which, when administered via the nasal passages and/or pharynx, bring about a physical reaction which is either so unpleasant for the patient that he/she does not wish to or cannot continue administration, for example burning, or physiologically counteracts taking of the corresponding active compound, for example due to increased nasal secretion or sneezing. Further examples of substances which irritate the nasal passages and/or pharynx are those which cause burning, itching, urge to sneeze, increased formation of secretions or a combination of at least two of these stimuli. Corresponding substances and the quantities thereof which are conventionally to be used are known to the person skilled in the art. Some of the substances which irritate the nasal passages and/or pharynx are accordingly based on one or more constituents or one or more plant parts of a hot substance drug. Corresponding hot substance drugs are known per se to the person skilled in the art and are described, for example, in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd., revised edition, Gustav Fischer Verlag, Stuttgart-N.Y., 1982, pages 82 et seq. The corresponding description is hereby introduced as a reference and is deemed to be part of the disclosure.
  • [0135]
    The pharmaceutical dosage form according to the invention furthermore preferably contains no antagonists for the opioid (A), preferably no antagonists against psychotropic substances, in particular no antagonists against opioids (A). Antagonists suitable for a given opioid (A) are known to the person skilled in the art and may be present as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. The pharmaceutical dosage form according to the invention preferably contains no antagonists selected from among the group comprising naloxone, naltrexone, nalmefene, nalide, nalmexone, nalorphine or naluphine, in each case optionally in the form of a corresponding physiologically acceptable compound, in particular in the form of a base, a salt or solvate; and no neuroleptics, for example a compound selected from among the group comprising haloperidol, promethacine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, chlorpromazine, chlorprothixine, zuclopenthixol, flupentixol, prothipendyl, zotepine, benperidol, pipamperone, melperone and bromperidol.
  • [0136]
    The pharmaceutical dosage form according to the invention furthermore preferably contains no emetic. Emetics are known to the person skilled in the art and may be present as such or in the form of corresponding derivatives, in particular esters or ethers, or in each case in the form of corresponding physiologically acceptable compounds, in particular in the form of the salts or solvates thereof. The pharmaceutical dosage form according to the invention preferably contains no emetic based on one or more constituents of ipecacuanha (ipecac) root, for example based on the constituent emetine, as are, for example, described in “Pharmazeutische Biologie—Drogen und ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart, N.Y., 1982. The corresponding literature description is hereby introduced as a reference and is deemed to be part of the disclosure. The pharmaceutical dosage form according to the invention preferably also contains no apomorphine as an emetic.
  • [0137]
    Finally, the pharmaceutical dosage form according to the invention preferably also contains no bitter substance. Bitter substances and the quantities effective for use may be found in US-2003/0064099 A1, the corresponding disclosure of which should be deemed to be the disclosure of the present application and is hereby introduced as a reference. Examples of bitter substances are aromatic oils, such as peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit aroma substances, aroma substances from lemons, oranges, limes, grapefruit or mixtures thereof, and/or denatonium benzoate.
  • [0138]
    The pharmaceutical dosage form according to the invention accordingly preferably contains neither substances which irritate the nasal passages and/or pharynx, nor antagonists for the opioid (A), nor emetics, nor bitter substances.
  • [0139]
    The pharmaceutical dosage form according to the invention is preferably adapted for oral administration.
  • [0140]
    Typically, the pharmaceutical dosage form according to the invention assumes the form of a tablet. Preferably, the pharmaceutical dosage form is neither in film form, nor multi-particulate.
  • [0141]
    The pharmaceutical dosage form according to the invention is preferably tamper-resistant. Preferably, tamper-resistance is achieved based on the mechanical properties of the pharmaceutical dosage form so that comminution is avoided or at least substantially impeded. According to the invention, the term comminution means the pulverization of the pharmaceutical dosage form using conventional means usually available to an abuser, for example a pestle and mortar, a hammer, a mallet or other conventional means for pulverizing under the action of force. Thus, tamper-resistance preferably means that pulverization of the pharmaceutical dosage form using conventional means is avoided or at least substantially impeded.
  • [0142]
    Preferably, the mechanical properties of the pharmaceutical dosage form according to the invention, particularly its breaking strength, substantially rely on the presence and spatial distribution of polyalkylene oxide (C), although its mere presence does typically not suffice in order to achieve said properties. The advantageous mechanical properties of the pharmaceutical dosage form according to the invention may not automatically be achieved by simply processing opioid (A), acid (B), polyalkylene oxide (C), and optionally further excipients by means of conventional methods for the preparation of pharmaceutical dosage forms. In fact, usually suitable apparatuses must be selected for the preparation and critical processing parameters must be adjusted, particularly pressure/force, temperature and time. Thus, even if conventional apparatuses are used, the process protocols usually must be adapted in order to meet the required criteria.
  • [0143]
    The pharmaceutical dosage form according to the invention has a breaking strength of at least 300 N, preferably at least 400 N, more preferably at least 500 N, still more preferably at least 750 N, yet more preferably at least 1000 N, most preferably at least 1250 N and in particular at least 1500 N.
  • [0144]
    The “breaking strength” (resistance to crushing) of a pharmaceutical dosage form is known to the skilled person. In this regard it can be referred to, e.g., W. A. Ritschel, Die Tablette, 2. Auflage, Editio Cantor Verlag Aulendorf, 2002; H Liebermann et al., Pharmaceutical dosage forms: Tablets, Vol. 2, Informa Healthcare; 2 edition, 1990; and Encyclopedia of Pharmaceutical Technology, Informa Healthcare; 1 edition.
  • [0145]
    For the purpose of the specification, the breaking strength is preferably defined as the amount of force that is necessary in order to fracture the pharmaceutical dosage form (=breaking force). Therefore, for the purpose of the specification the pharmaceutical dosage form does preferably not exhibit the desired breaking strength when it breaks, i.e., is fractured into at least two independent parts that are separated from one another. In another preferred embodiment, however, the pharmaceutical dosage form is regarded as being broken if the force decreases by 25% (threshold value) of the highest force measured during the measurement (see below).
  • [0146]
    The pharmaceutical dosage forms according to the invention are distinguished from conventional pharmaceutical dosage forms in that, due to their breaking strength, they cannot be pulverized by the application of force with conventional means, such as for example a pestle and mortar, a hammer, a mallet or other usual means for pulverization, in particular devices developed for this purpose (tablet crushers). In this regard “pulverization” means crumbling into small particles that would immediately release the pharmacologically active compound (A) in a suitable medium. Avoidance of pulverization virtually rules out oral or parenteral, in particular intravenous or nasal abuse.
  • [0147]
    Conventional tablets typically have a breaking strength well below 200 N in any direction of extension. The breaking strength of conventional round tablets may be estimated according to the following empirical formula: Breaking Strength [in N]=10×Diameter Of The Tablet [in mm]. Thus, according to said empirical formula, a round tablet having a breaking strength of at least 300 N would require a diameter of at least 30 mm). Such a tablet, however, could not be swallowed. The above empirical formula preferably does not apply to the pharmaceutical dosage forms of the invention, which are not conventional but rather special.
  • [0148]
    Further, the actual mean chewing force is about 220 N (cf., e.g., P. A. Proeschel et al., J Dent Res, 2002, 81(7), 464-468). This means that conventional tablets having a breaking strength well below 200 N may be crushed upon spontaneous chewing, whereas the pharmaceutical dosage forms according to the invention may not.
  • [0149]
    Still further, when applying a gravitational acceleration of about 9.81 m/s2, 300 N correspond to a gravitational force of more than 30 kg, i.e. the pharmaceutical dosage forms according to the invention can preferably withstand a weight of more than 30 kg without being pulverised.
  • [0150]
    Methods for measuring the breaking strength of a pharmaceutical dosage form are known to the skilled artisan. Suitable devices are commercially available.
  • [0151]
    For example, the breaking strength (resistance to crushing) can be measured in accordance with the Eur. Ph. 5.0, 2.9.8 or 6.0, 2.09.08 “Resistance to Crushing of Tablets”. The test is intended to determine, under defined conditions, the resistance to crushing of tablets, measured by the force needed to disrupt them by crushing. The apparatus consists of 2 jaws facing each other, one of which moves towards the other. The flat surfaces of the jaws are perpendicular to the direction of movement. The crushing surfaces of the jaws are flat and larger than the zone of contact with the tablet. The apparatus is calibrated using a system with a precision of 1 Newton. The tablet is placed between the jaws, taking into account, where applicable, the shape, the break-mark and the inscription; for each measurement the tablet is oriented in the same way with respect to the direction of application of the force (and the direction of extension in which the breaking strength is to be measured). The measurement is carried out on 10 tablets, taking care that all fragments of tablets have been removed before each determination. The result is expressed as the mean, minimum and maximum values of the forces measured, all expressed in Newton.
  • [0152]
    A similar description of the breaking strength (breaking force) can be found in the USP. The breaking strength can alternatively be measured in accordance with the method described therein where it is stated that the breaking strength is the force required to cause a tablet to fail (i.e., break) in a specific plane. The tablets are generally placed between two platens, one of which moves to apply sufficient force to the tablet to cause fracture. For conventional, round (circular cross-section) tablets, loading occurs across their diameter (sometimes referred to as diametral loading), and fracture occurs in the plane. The breaking force of tablets is commonly called hardness in the pharmaceutical literature; however, the use of this term is misleading. In material science, the term hardness refers to the resistance of a surface to penetration or indentation by a small probe. The term crushing strength is also frequently used to describe the resistance of tablets to the application of a compressive load. Although this term describes the true nature of the test more accurately than does hardness, it implies that tablets are actually crushed during the test, which is often not the case.
  • [0153]
    Alternatively, the breaking strength (resistance to crushing) can be measured in accordance with WO 2005/ 016313, WO 2005/016314, and WO 2006/082099, which can be regarded as a modification of the method described in the Eur. Ph. The apparatus used for the measurement is preferably a “Zwick Z 2.5” materials tester, Fmax=2.5 kN with a maximum draw of 1150 mm, which should be set up with one column and one spindle, a clearance behind of 100 mm and a test speed adjustable between 0.1 and 800 mm/min together with testControl software. Measurement is performed using a pressure piston with screw-in inserts and a cylinder (diameter 10 mm), a force transducer, Fmax. 1 kN, diameter=8 mm, class 0.5 from 10 N, class 1 from 2 N to ISO 7500-1, with manufacturers test certificate M according to DIN 55350-18 (Zwick gross force Fmax=1.45 kN) (all apparatus from Zwick GmbH & Co. KG, Ulm, Germany) with Order No BTC-FR 2.5 TH. D09 for the tester, Order No BTC-LC 0050N. P01 for the force transducer, Order No BO 70000 S06 for the centring device.
  • [0154]
    In a preferred embodiment of the invention, the breaking strength is measured by means of a breaking strength tester e.g. Sotax®, type HT100 or type HT1 (Allschwil, Switzerland). Both, the Sotax® HT100 and the Sotax® HT1can measure the breaking strength according to two different measurement principles: constant speed (where the test jaw is moved at a constant speed adjustable from 5-200 mm/min) or constant force (where the test jaw increases force linearly adjustable from 5-100 N/sec). In principle, both measurement principles are suitable for measuring the breaking strength of the pharmaceutical dosage form according to the invention. Preferably, the breaking strength is measured at constant speed, preferably at a constant speed of 120 mm/min.
  • [0155]
    In a preferred embodiment, the pharmaceutical dosage form is regarded as being broken if it is fractured into at least two separate pieces.
  • [0156]
    The pharmaceutical dosage form according to the invention preferably exhibits mechanical strength over a wide temperature range, in addition to the breaking strength (resistance to crushing) optionally also sufficient hardness, impact resistance, impact elasticity, tensile strength and/or modulus of elasticity, optionally also at low temperatures (e.g. below −24° C., below −40° C. or in liquid nitrogen), for it to be virtually impossible to pulverize by spontaneous chewing, grinding in a mortar, pounding, etc. Thus, preferably, the comparatively high breaking strength of the pharmaceutical dosage form according to the invention is maintained even at low or very low temperatures, e.g., when the pharmaceutical dosage form is initially chilled to increase its brittleness, for example to temperatures below −25° C., below −40° C. or even in liquid nitrogen.
  • [0157]
    The pharmaceutical dosage form according to the invention is characterized by a certain degree of breaking strength. This does not mean that the pharmaceutical dosage form must also exhibit a certain degree of hardness. Hardness and breaking strength are different physical properties. Therefore, the tamper resistance of the pharmaceutical dosage form does not necessarily depend on the hardness of the pharmaceutical dosage form. For instance, due to its breaking strength, impact strength, elasticity modulus and tensile strength, respectively, the pharmaceutical dosage form can preferably be deformed, e.g. plastically, when exerting an external force, for example using a hammer, but cannot be pulverized, i.e., crumbled into a high number of fragments. In other words, the pharmaceutical dosage form according to the invention is characterized by a certain degree of breaking strength, but not necessarily also by a certain degree of form stability.
  • [0158]
    Therefore, in the meaning of the specification, a pharmaceutical dosage form that is deformed when being exposed to a force in a particular direction of extension but that does not break (plastic deformation or plastic flow) is preferably to be regarded as having the desired breaking strength in said direction of extension.
  • [0159]
    A particularly preferred embodiment of the invention relates to a tamper-resistant pharmaceutical dosage form having a breaking strength of at least 300 N and being thermoformed by hot-melt extrusion, said pharmaceutical dosage form comprising
      • an opioid (A) selected from the group consisting of oxymorphone, oxycodone, hydromorphone, and the physiologically acceptable salts thereof;
      • a free physiologically acceptable multicarboxylic acid (B), preferably citric acid, wherein the content of the acid (B) is within the range of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form;
      • an antioxidant, wherein the content of the antioxidant, preferably α-tocopherol, is within the range of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form; and
      • a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol;
  • [0164]
    wherein
      • the opioid (A) is embedded in a matrix comprising the polyalkylene oxide (C), said matrix controlling the release of the opioid (A) from the pharmaceutical dosage form; and
      • after storage for 4 weeks at 40° C. and 75% rel. humidity, the content of opioid (A) amounts to at least 98.0% of its original content before storage.
  • [0167]
    The pharmaceutical dosage form according to the invention may be produced by different processes, the particularly preferred of which are explained in greater detail below. Several suitable processes have already been described in the prior art. In this regard it can be referred to, e.g., WO 2005/ 016313, WO 2005/016314, WO 2005/063214, WO 2005/102286, WO 2006/002883, WO 2006/002884, WO 2006/002886, WO 2006/082097, and WO 2006/082099.
  • [0168]
    The present invention also relates to pharmaceutical dosage forms that are obtainable by any of the processes described here below.
  • [0169]
    In general, the process for the production of the pharmaceutical dosage form according to the invention preferably comprises the following steps:
      • (a) mixing all ingredients;
      • (b) optionally pre-forming the mixture obtained from step (a), preferably by applying heat and/or force to the mixture obtained from step (a), the quantity of heat supplied preferably not being sufficient to heat the polyalkylene oxide (C) up to its softening point;
      • (c) hardening the mixture by applying heat and force, it being possible to supply the heat during and/or before the application of force and the quantity of heat supplied being sufficient to heat the polyalkylene oxide (C) at least up to its softening point;
      • (d) optionally singulating the hardened mixture;
      • (e) optionally shaping the pharmaceutical dosage form; and
      • (f) optionally providing a film coating.
  • [0176]
    Heat may be supplied directly, e.g. by contact or by means of hot gas such as hot air, or with the assistance of ultrasound. Force may be applied and/or the pharmaceutical dosage form may be shaped for example by direct tabletting or with the assistance of a suitable extruder, particularly by means of a screw extruder equipped with two screws (twin-screw-extruder) or by means of a planetary gear extruder.
  • [0177]
    The final shape of the pharmaceutical dosage form may either be provided during the hardening of the mixture by applying heat and force (step (c)) or in a subsequent step (step (e)). In both cases, the mixture of all components is preferably in the plastified state, i.e. preferably, shaping is performed at a temperature at least above the softening point of the polyalkylene oxide (C). However, extrusion at lower temperatures, e.g. ambient temperature, is also possible and may be preferred.
  • [0178]
    Shaping can be performed, e.g., by means of a tabletting press comprising die and punches of appropriate shape.
  • [0179]
    A particularly preferred process for the manufacture of the pharmaceutical dosage form of the invention involves hot-melt extrusion. In this process, the pharmaceutical dosage form according to the invention is produced by thermoforming with the assistance of an extruder, preferably without there being any observable consequent discoloration of the extrudate. It has been surprisingly found that acid (B) is capable of suppressing discoloration. In the absence of acid (B), the extrudate tends to develop beige to yellowish coloring whereas in the presence of acid (B) the extrudates are substantially colorless, i.e. white.
  • [0180]
    This process is characterized in that
      • a) all components are mixed,
      • b) the resultant mixture is heated in the extruder at least up to the softening point of the polyalkylene oxide (C) and extruded through the outlet orifice of the extruder by application of force,
      • c) the still plastic extrudate is singulated and formed into the pharmaceutical dosage form or
      • d) the cooled and optionally reheated singulated extrudate is formed into the pharmaceutical dosage form.
  • [0185]
    Mixing of the components according to process step a) may also proceed in the extruder.
  • [0186]
    The components may also be mixed in a mixer known to the person skilled in the art. The mixer may, for example, be a roll mixer, shaking mixer, shear mixer or compulsory mixer.
  • [0187]
    Before blending with the remaining components, polyalkylene oxide (C) is preferably provided according to the invention with an antioxidant, preferably α-tocopherol. This may proceed by mixing the two components, the polyalkylene oxide (C) and the antioxidant, preferably by dissolving or suspending the antioxidant in a highly volatile solvent and homogeneously mixing this solution or suspension with polyalkylene oxide (C) and removing the solvent by drying, preferably under an inert gas atmosphere.
  • [0188]
    The, preferably molten, mixture which has been heated in the extruder at least up to the softening point of polyalkylene oxide (C) is extruded from the extruder through a die with at least one bore.
  • [0189]
    The process according to the invention requires the use of suitable extruders, preferably screw extruders. Screw extruders which are equipped with two screws (twin-screw-extruders) are particularly preferred.
  • [0190]
    The extrusion is preferably performed so that the expansion of the strand due to extrusion is not more than 30%, i.e. that when using a die with a bore having a diameter of e.g. 6 mm, the extruded strand should have a diameter of not more than 8 mm. More preferably, the expansion of the strand is not more than 25%, still more preferably not more than 20%, most preferably not more than 15% and in particular not more than 10%.
  • [0191]
    Preferably, extrusion is performed in the absence of water, i.e., no water is added. However, traces of water (e.g., caused by atmospheric humidity) may be present.
  • [0192]
    The extruder preferably comprises at least two temperature zones, with heating of the mixture at least up to the softening point of the polyalkylene oxide (C) proceeding in the first zone, which is downstream from a feed zone and optionally mixing zone. The throughput of the mixture is preferably from 1.0 kg to 15 kg/hour. In a preferred embodiment, the throughput is from 1 to 3.5 kg/hour. In another preferred embodiment, the throughput is from 4 to 15 kg/hour.
  • [0193]
    In a preferred embodiment, the die head pressure is within the range of from 25 to 100 bar. The die head pressure can be adjusted inter alia by die geometry, temperature profile and extrusion speed.
  • [0194]
    The die geometry or the geometry of the bores is freely selectable. The die or the bores may accordingly exhibit a round, oblong or oval cross-section, wherein the round cross-section preferably has a diameter of 0.1 mm to 15 mm and the oblong cross-section preferably has a maximum lengthwise extension of 21 mm and a crosswise extension of 10 mm. Preferably, the die or the bores have a round cross-section. The casing of the extruder used according to the invention may be heated or cooled. The corresponding temperature control, i.e. heating or cooling, is so arranged that the mixture to be extruded exhibits at least an average temperature (product temperature) corresponding to the softening temperature of the polyalkylene oxide (C) and does not rise above a temperature at which the opioid (A) to be processed may be damaged. Preferably, the temperature of the mixture to be extruded is adjusted to below 180° C., preferably below 150° C., but at least to the softening temperature of polyalkylene oxide (C). Typical extrusion temperatures are 120° C. and 130° C.
  • [0195]
    In a preferred embodiment, the extruder torque is within the range of from 30 to 95%. Extruder torque can be adjusted inter alia by die geometry, temperature profile and extrusion speed.
  • [0196]
    After extrusion of the molten mixture and optional cooling of the extruded strand or extruded strands, the extrudates are preferably singulated. This singulation may preferably be performed by cutting up the extrudates by means of revolving or rotating knives, water jet cutters, wires, blades or with the assistance of laser cutters.
  • [0197]
    Preferably, intermediate or final storage of the optionally singulated extrudate or the final shape of the pharmaceutical dosage form according to the invention is performed under oxygen-free atmosphere which may be achieved, e.g., by means of oxygen-scavengers.
  • [0198]
    The singulated extrudate may be press-formed into tablets in order to impart the final shape to the pharmaceutical dosage form.
  • [0199]
    The application of force in the extruder onto the at least plasticized mixture is adjusted by controlling the rotational speed of the conveying device in the extruder and the geometry thereof and by dimensioning the outlet orifice in such a manner that the pressure necessary for extruding the plasticized mixture is built up in the extruder, preferably immediately prior to extrusion. The extrusion parameters which, for each particular composition, are necessary to give rise to a pharmaceutical dosage form with desired mechanical properties, may be established by simple preliminary testing.
  • [0200]
    For example but not limiting, extrusion may be performed by means of a twin-screw-extruder type ZSE 18 or ZSE27 (Leistritz, Nürnberg, Germany), screw diameters of 18 or 27 mm. Screws having eccentric ends may be used. A heatable die with a round bore having a diameter of 7, 8, or 9 mm may be used. The extrusion parameters may be adjusted e.g. to the following values: rotational speed of the screws: 120 Upm; delivery rate 2 kg/h for a ZSE 18 or 8 kg/h for a ZSE27; product temperature: in front of die 125° C. and behind die 135° C.; and jacket temperature: 110° C.
  • [0201]
    Preferably, extrusion is performed by means of twin-screw-extruders or planetary-gear-extruders, twin-screw extruders (co-rotating or contra-rotating) being particularly preferred.
  • [0202]
    The pharmaceutical dosage form according to the invention is preferably produced by thermoforming with the assistance of an extruder without any observable consequent discoloration of the extrudates.
  • [0203]
    The process for the preparation of the pharmaceutical dosage form according to the invention is preferably performed continuously. Preferably, the process involves the extrusion of a homogeneous mixture of all components. It is particularly advantageous if the thus obtained intermediate, e.g. the strand obtained by extrusion, exhibits uniform properties. Particularly desirable are uniform density, uniform distribution of the active compound, uniform mechanical properties, uniform porosity, uniform appearance of the surface, etc. Only under these circumstances the uniformity of the pharmacological properties, such as the stability of the release profile, may be ensured and the amount of rejects can be kept low.
  • [0204]
    A further aspect of the invention relates to a packaging containing a pharmaceutical dosage form according to the invention and an oxygen scavenger. Suitable packages include blister packages and bottles, such as glass bottles or bottles made from thermoplastic polymers.
  • [0205]
    Suitable oxygen scavengers are known to the skilled artisan. The oxygen scavenger can be any scavenger known in the art to scavenge oxygen. Both organic and inorganic oxygen scavengers can be used.
  • [0206]
    In one embodiment, the oxygen scavenger is any metal complex exhibiting oxygen scavenging activity. Examples include complexes containing one or more of aluminum, aluminum ferrosilicon, antimony, beryllium, calcium silicon, cerium, cobalt, gallium, hafnium, iron, magnesium alloy, nickel catalyst, selenium, silicon, silver, strontium, titanium, zinc, and/or zirconium.
  • [0207]
    In yet another embodiment, one or more elements from Group IA of the periodic table and their alloys and compounds may be used as oxygen scavengers. Examples of Group IA elements include cesium, lithium, potassium, sodium. Further examples of inorganic oxygen scavengers include one or more of sodium azide (NaN3), sodium sulfite (Na2SO3), hydrazine, and hydroxylamine.
  • [0208]
    In one embodiment, the oxygen scavenger is an organic compound. Examples include one or more of the polyterpenes, ascorbic acid, amino polycarboxylic acid, cyclohexanedione, tetramethyl piperidone, and heterocyclic compounds with N-substituted amino groups.
  • [0209]
    Oxygen scavengers and the application thereof in pharmaceutical packaging are known to the skilled artisan. In a preferred embodiment, the oxygen scavenger is selected from the group consisting of metal-catalyzed oxidizable organic polymers and anti-oxidants. Particularly preferred are those oxygen scavengers that are able to perform in a dry environment of below 60% relative humidity, preferably below 30% relative humidity and that are combined with a dessicant. Examples of commercially available oxygen scavengers satisfying these requirements include Pharmakeep® KD10 and KD20.
  • [0210]
    It has been surprisingly found that the storage stability of the pharmaceutical dosage form can be increased when keeping the oxygen content of the atmosphere within the packaging low. Methods for packaging pharmaceutical dosage forms and the application of suitable oxygen scavengers are known to the skilled artisan. In this regard it can be referred to e.g. D. A. Dean, Pharmaceutical Packaging Technology, Taylor & Francis, 1st ed.; F. A. Paine et al., Packaging Pharmaceutical and Healthcare Products, Springer, 1st ed.; and O. G. Piringer et al., Plastic Packaging: Interactions with Food and Pharmaceuticals, Wiley-VCH, 2nd ed.
  • [0211]
    As far as the packaging is concerned, round bottles made from polyolefins, preferably from
  • [0212]
    HDPE, are preferred. The thickness of the bottle wall is preferably at least 0.25 mm, more preferably at least 0.5 mm, otherwise the bottle may collapse.
  • [0213]
    As far as the lid of the packaging is concerned, the packaging is preferably induction or heat-sealed with an aluminium foil.
  • [0214]
    It has been surprisingly found that by selecting an appropriate shape of the packaging and sealing, the vacuum that is produced by the effect of the oxygen scavenger (underpressure of about 20,000 Pa=2 N/cm2) can be handled without causing a collapse of the packaging. Induction sealing (e.g. 3 seconds energy) is preferred. When sealing a 75 ml bottle having an opening with a diameter of 1 inch with aluminium foil, an underpressure of 20,000 Pa due to oxygen scavenging results in a force of about 10 N corresponding to the force that is exerted by a weight of 1 kg.
  • [0215]
    The mechanical stability of the sealing can be tested either by introducing an appropriate amount of oxygen scavenger in the bottle, sealing it and waiting for a sufficient period of time, e.g. 2 days, so that the oxygen is scavenged and an underpressure of about 20,000 has been developed. Alternatively, the bottle may be sealed without any oxygen scavenger in its interior and a weight of 1 kg can be placed on the aluminium foil externally thus, simulating the force.
  • [0216]
    A further aspect of the invention relates to the use of an opioid (A) for the manufacture of the pharmaceutical dosage form as described above for the treatment of pain.
  • [0217]
    A further aspect of the invention relates to the use of a pharmaceutical dosage form as described above for avoiding or hindering the abuse of the opioid (A) contained therein.
  • [0218]
    A further aspect of the invention relates to the use of a pharmaceutical dosage form as described above for avoiding or hindering the unintentional overdose of the opioid (A) contained therein.
  • [0219]
    In this regard, the invention also relates to the use of a opioid (A) as described above and/or a polyalkylene oxide (C) as described above for the manufacture of the pharmaceutical dosage form according to the invention for the prophylaxis and/or the treatment of a disorder, thereby preventing an overdose of the opioid (A), particularly due to comminution of the pharmaceutical dosage form by mechanical action.
  • [0220]
    Further, the invention relates to a method for the prophylaxis and/or the treatment of a disorder comprising the administration of the pharmaceutical dosage form according to the invention, thereby preventing an overdose of the opioid (A), particularly due to comminution of the pharmaceutical dosage form by mechanical action. Preferably, the mechanical action is selected from the group consisting of chewing, grinding in a mortar, pounding, and using apparatuses for pulverizing conventional pharmaceutical dosage forms.
  • [0221]
    The following examples further illustrate the invention but are not to be construed as limiting its scope.
  • EXAMPLE 1
  • [0222]
    Tablets were prepared by hot-melt extrusion of various homogeneous constituent mixtures under the following, identical extrusion conditions:
      • extruder type: Leistritz Extruder ZSE18PH 40D equipped with high shear screws and a die of 9 mm diameter
      • throughput: 1.0 kg/h
      • revolution velocity: 100 rpm
      • barrel temperature: 100° C.
      • extrudate temperature: 120° C.
  • [0228]
    The extrudate was cut into slices of 325 mg containing about 5 mg oxymorphone hydrochloride.
  • [0229]
    The individual constituents of the extruded mixtures as well as the total amount of decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    further
    constituents (wt.-%) ingredient decomposition products (wt.-%)
    ex. (A) PEO PEG HPMC α-toc. (wt.-%) oNo1 oNo2 Σ1 Σ2
    A1 1.5 76.9 10.0 10.0 1.5 / 0.06 0.58 0.41 1.93
    A2 1.5 77.5 10.0 10.0 1.0 / 0.09 0.49 0.58 1.81
    A3 1.5 78.0 10.0 10.0 0.5 / 0.08 0.36 0.56 1.64
    A4 1.5 78.3 10.0 10.0 0.2 / 0.08 0.26 0.63 1.51
    A5 1.5 78.5 10.0 10.0 0.0 / 0.07 0.17 0.81 1.69
    B1 1.5 76.9 10.0 10.0 1.5 / 0.06 0.58 0.41 1.93
    B2 1.5 40.0 10.0 46.9 1.5 / 0.09 0.55 0.64 1.76
    B3 1.5 50.0 10.0 36.9 1.5 / 0.00 0.52 0.29 1.64
    B4 1.5 50.0 36.9 10.0 1.5 / 0.11 0.76 0.36 1.74
    C1 1.5 76.9 10.0 10.0 1.5 / 0.06 0.58 0.41 1.93
    C2 1.5 76.9 / 10.0 1.5 10.00 Lutrol ® F68 0.05 0.53 0.65 1.83
    C3 1.5 50.0 10.0 10.0 1.5 26.90 mannitol 0.08 0.82 0.39 2.72
    C4 1.5 76.9 / 10.0 1.5 10.00 carnaubawax 0.12 0.53 0.39 1.03
    D1 1.5 76.9 10.0 10.0 1.5 / 0.06 0.58 0.41 1.93
    D2 1.5 76.8 10.0 10.0 1.5 0.10 fumaric acid 0.05 0.48 0.52 1.70
    D3 1.5 76.8 10.0 10.0 1.5 0.10 Na-EDTA 0.07 0.51 0.48 1.77
    D4 1.5 76.8 10.0 10.0 1.5 0.10 citric acid 0.07 0.48 0.37 1.45
    E1 1.5 76.9 10.0 10.0 1.5 / 0.06 0.58 0.41 1.93
    E2 1.5 76.8 10.0 10.0 1.5 0.10 citric acid 0.07 0.48 0.37 1.45
    E3 1.5 76.7 10.0 10.0 1.5 0.20 citric acid 0.00 0.40 0.20 1.13
    E4 1.5 76.4 10.0 10.0 1.5 0.50 citric acid 0.00 0.06 0.12 0.17
    (A): oxymorphone hydrochloride
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC: hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    oNo: oxymorphone-N-oxide (mixture)
    Σ: sum of all impurities
    1after extrusion, before storage
    2after storage, amber glass bottles, plastic cap, 4 weeks, 40° C., 75% rel. humidity
  • [0230]
    The decomposition products were analyzed by HPLC-UV. The elution peak for oxymor-phone-N-oxide could not be sufficiently base-line separated from a peak of an unknown degradation product (called “UK 0.83”). Thus, both peaks were jointly integrated. It becomes evident from a comparison of examples A1 to A5 that the content of oxymorphone-N-oxide before storage (oNo1) is not substantially changed when the content of antioxidant α-tocopherol is decreased from 1.5 wt.-% to 1.0 wt.-%, 0.5 wt.-%, 0.2 wt.-% and even 0 wt.-%. Upon storage (oNo2), however, the content of oxymorphone-N-oxide is proportional to the content of α-tocopherol. This is most surprising because oxymorphone-N-oxide is an oxidation product and one would expect that antioxidants usually rather suppress than support the formation of oxidation products.
  • [0231]
    Nonetheless, the complete omission of antioxidant (α-tocopherol) has disadvantages. It could be shown by viscosity measurements that the high molecular polyethylene oxide is degraded upon extrusion and/or storage in the absence of antioxidant. It has been surprisingly found that about 0.2 wt.-% α-tocopherol suffice in order to stabilize the polyethylene oxide; higher contents of α-tocopherol do not result in higher viscosities of the polyalkylene oxide and, thus, do not prevent PEO more pronounced from degradation. Thus, the content of antioxidant (α-tocopherol) is preferably balanced so that on the one side, the high molecular weight polyethylene oxide is sufficiently stabilized and that on the other side, the undesired formation of oxymorphone-N-oxide is kept low during storage.
  • [0232]
    Further, it becomes evident from a comparison of examples B1 to B4 and examples C1 to C4 that the partial replacement of the high molecular weight polyethylene oxide or the total replacement of the polyethylene glycol by an alternative plasticizer does not result in a substantial decrease of the content of undesired oxymorphone-N-oxide. This is surprising because one would expect that polyethylene oxide and polyethylene glycol are potential peroxide carriers and that a reduction thereof would result in a reduction of oxidative processes such as the oxidation of oxymorphone to oxymorphone-N-oxide.
  • [0233]
    Still further, it becomes evident from a comparison of examples D1 to D5 and E1 to E4 that the addition of physiologically acceptable acids, particularly citric acid, leads to a reduction of the formation of oxymorphone-N-oxide. This effect is more pronounced when the amount of acid is increased. At a concentration of 0.1 wt.-%, the effect is comparatively weak, but at a concentration of 0.2 wt.-% the effect is stronger and is further enhanced when the concentration of citric acid is increased. Not only the amount of oxymorphone-N-oxide is decreased, but also the total amount of decomposition products, particularly of those having high HPLC retention times.
  • EXAMPLE 2
  • [0234]
    Tablets that had been manufactured in analogy to ex. A1, B1, C1, D1 and E1 above were packaged in different packaging materials and stored at 40° C. and 75% rel. humidity. The decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    closed HDPE, sealed closed amber glass + closed amber closed amber
    before with aluminium foil open amber glass oxygen scavenger glass + desiccant glass + argon
    storage 4 weeks 8 weeks 4 weeks 8 weeks 4 weeks 8 weeks 4 weeks 8 weeks 4 weeks 8 weeks
    323.64 mg 324.05 mg 325.57 mg 323.56 mg 337.25 mg 325.23 mg 322.65 mg 321.27 mg 322.69 mg 324.62 mg 324.30 mg
    content 96.30% 92.90% 89.40% 93.70% 88.50% 96.70% 94.80% 94.60% 92.50% 94.60% 92.50%
    oxymorphone
    purity 99.18% 97.70% 96.70% 98.03% 94.50% 99.10% 98.62% 98.59% 97.98% 98.36% 98.04%
    oxymorphone
    content 91.69% 91.51% 90.89% 93.51% 79.94% 94.52% 93.62% 90.56% 88.23% 93.51% 92.18%
    α-tocopherol
    oxymor- 0.09% 0.64% 1.16% 0.19% 0.53% 0.03% 0.04% 0.15% 0.24% 0.17% 0.30%
    phone-N-oxide
    UK 0.83 0.00% 0.00% 0.00% 0.36% 2.15% 0.06% 0.08% 0.32% 0.77% 0.00% 0.00%
    Sum of oxymor- 0.09% 0.64% 1.16% 0.55% 2.63% 0.09% 0.12% 0.37% 1.01% 0.17% 0.30%
    phone-N-
    oxide and
    UK 0.83
    main unknown 0.13% 0.38% 0.43% 0.45% 2.15% 0.16% 0.18% 0.32% 0.77% 0.46% 0.34%
    Sum of 0.73% 2.22% 3.21% 1.88% 5.44% 0.82% 0.95% 1.33% 1.94% 1.55% 1.88%
    impurities Σ
    HDPE bottles had a volume of 75 ml. The oxygen scavenger was Pharmakeep ® KD20 (Mitsubishi, Japan).
  • [0235]
    It has been surprisingly found that inclusion of an oxygen scavenger in the packaging results in a further stabilization of the dosage form so that the formation of decomposition products is limited to extremely low values.
  • EXAMPLE 3
  • [0236]
    Tablets were manufactured as described in example 1, packed into HDPE bottles of 75 ml volume together with an oxygen scavenger combined with a desiccant (Pharmakeep 20 KD), closed with a plastic cap with induction seal.
  • [0237]
    The individual constituents of the extruded mixtures, the total amount of decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    constituents (wt.-%) decomposition products (wt.-%)
    ex. (A) PEO PEG HPMC α-toc. Citric acid oNo1 oNo2 oNo3 Σ1 Σ2 Σ3
    F1 1.5 73.8 10.0 14.0 0.2 0.5 nd nd nd nd nd 0.05
    F2 1.5 77.8 10.0 10.0 0.2 0.5 nd nd nd nd 0.05 0.10
    (A): oxymorphone hydrochloride
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC: hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    oNo: oxymorphone-N-oxide (mixture)
    Σ: sum of all impurities
    1after extrusion, before storage
    2after storage, HDPE bottles, plastic cap with induction seal, oxygen scavenger, 4 weeks, 40° C., 75% rel. humidity
    3after storage, HDPE bottles, plastic cap with induction seal, oxygen scavenger, 8 weeks, 40° C., 75% rel. humidity
  • [0238]
    The results reveal that the purity of the product is very high after manufacturing and that the product exhibit stable during 8 weeks storage under accelerated conditions of 40° C./75% rel. humidity.
  • EXAMPLE 4
  • [0239]
    Tablets were manufactured as described in example 1 but cut into slices of 215 mg representing 5 mg or 40 mg of oxymorphone HCl, after forming the tablets were coated with about 6.5 mg each of a conventional Opadry II film-coat containing polyvinylalcohol as the film forming excipient, packed into HDPE bottles of 75 ml volume together with an oxygen scavenger combined with a desiccant (Pharmakeep 20 KD), closed with a plastic cap with induction seal.
  • [0240]
    The individual constituents of the extruded mixtures, the total amount of decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    constituents (wt.-%) decomposition products (wt.-%)
    ex. (A) PEO PEG HPMC α-toc. Citric acid oNo1 oNo2 Σ1 Σ2
    G1 2.33 70.0 16.63 10.0 0.2 0.84 nd nd nd nd
    G2 18.6 56.8 13.56 10.0 0.2 0.84 nd nd 0.05 0.05
    (A): oxymorphone hydrochloride
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC: hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    oNo: oxymorphone-N-oxide (mixture)
    Σ: sum of all impurities
    1after extrusion, before storage
    2after storage, HDPE bottles, plastic cap with induction seal, oxygen scavenger, 1 month, 40° C., 75% rel. humidity
  • EXAMPLE 5
  • [0241]
    The most preferred dosage form according to example 3 is also suitable for the stabilization of oxycodone. This could be demonstrated for a formulation containing 80 mg of oxycodone HCl manufactured analogue to example 1 but, the extrudate was cut into slices of 400 mg:
  • [0000]
    constituents (wt.-%) decomposition products (wt.-%)
    ex. (A) PEO PEG HPMC α-toc. Citric acid oNo1 oNo2 Σ1 Σ2
    H1 20 54.3 15 10 0.2 0.5 0.06 0.07 0.22 0.13
    (A): oxycodone
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC: hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    oNo: oxycodone-N-oxide (Impurity D + E)
    1after extrusion, before storage
    2after storage, amber glass bottles, plastic cap, oxygen scavenger with desiccant (Pharmakeep 20KD) 1 month, 40° C., 75% rel. humidity
  • EXAMPLE 6
  • [0242]
    In a single dose (40 mg oxymorphone HCl, tablets of example 4), randomized, three-way crossover study with 1 week between treatments subjects were fasted overnight and meals were served 4 and 10 hours after dosing. No water was given within±1 hour of dosing. All tablets were taken with 240 mL of water (example T).
  • [0243]
    PK samples were taken for oxymorphone and 6-OH-oxymorphone predose and up through 48 hours after dosing.
  • [0244]
    Bioequivalence was compared to Opana ER® (reference R).
  • [0245]
    The results are summarized in the tables here below:
  • [0000]
    Treatment Mean SD CV
    Cmax [pg/mL] T 2147 989 46%
    R 2671 1163 44%
    AUCT [pg*h/mL] T 38695 13836 36%
    R 38171 14652 38%
    AUC [pg*h/mL] T 42575 15836 37%
    R 41296 15242 37%
  • [0000]
    Point Estimate Lower Limit Upper Limit
    T/R 90% CI 90% CI
    Cmax 79.37 71.69 87.87
    AUCT 101.98 95.17 109.29
    AUC 102.24 95.48 109.48
    CI = confidence interval
  • [0246]
    It becomes evident that the dosage forms according to the invention having an increased breaking strength are bioequivalent to conventional dosage forms (Opana ER®).
  • EXAMPLE 7
  • [0247]
    Tablets were prepared under identical conditions by hot-melt extrusion of two homogeneous constituent mixtures I1 and I2:
  • [0000]
    I1 I2
    Oxymorphone HCl [%] 11.1 11.1
    PEO [%] 68.2 63.2
    PEG [%] 10.0 15.0
    HPMC Shin Etsu [%] 10.0 10.0
    α-tocopherol [%] 0.2 0.2
    Citric acid, anhydrous [%] 0.5 0.5
    Tablet weight [mg] 360 360
    PEO:PEG 6.82:1 4.21:1

    under the following, identical extrusion conditions:
      • extruder type: Leistritz Extruder type Micro 27 GL 40 D equipped with medium shear screws and a die of 8 mm diameter throughput: 10 kg/h
      • revolution velocity: 120 rpm
      • manufacturing time: 30 min
      • temperature of hottest heating zone: 100° C.
      • die temperature: 130° C.
  • [0253]
    The extrudate was cut into slices of 360 mg containing about 40 mg oxymorphone hydrochloride.
  • [0254]
    100 slices were weighed individually and the standard deviation of weight was calculated.
  • [0255]
    Slices of composition I1 (PEO:PEG=6.82:1) showed a standard deviation of 2.3%, whereas slices of composition I2 (PEO:PEG=4.21:1) showed a standard deviation of 1.6% only.
  • [0256]
    It becomes evident from these comparative tests that surprisingly, the processability of the extruded mass can be improved by adjusting the ratio of PEO to PEG.
  • EXAMPLE 8
  • [0257]
    In order to investigate if also multicarboxylic acids other than citric acid could hamper the formation of oxymorphone-N-oxide, tablets containing maleinic acid or fumaric acid were manufactured as described in example 1. For comparison, also tablets containing the inorganic salt NaH2PO4 were manufactured. The samples were stored in open dishes at 40° C. and 75% relative humidity for 4 weeks.
  • [0258]
    The individual constituents of the extruded mixtures as well as the total amount of decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    constituents (wt.-%) further decomposition products (wt-%)
    ex. (A) PEO PEG HPMC α-toc. ingredient (wt.-%) oNo1 oNo2 Σ1 Σ2
    J1 1.5 76.0 10.0 10.0 1.5 Maleinic acid 1.0% nd nd 0.20 0.22
    J2 1.5 76.0 10.0 10.0 1.5 Fumaric acid 1.0% nd nd 0.17 0.30
    J3 1.5 76.0 10.0 10.0 1.5 NaH2PO4 1.0%* nd 0.18 0.06 0.75
    (A): oxymorphone hydrochloride
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC : hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    *NaH2PO4: Used in form of 1.3% of the di-hydrate
    oNo: oxymorphone-N-oxide (mixture)
    Σ: sum of all impurities; maleinic acid, fumaric acid and related compounds subtracted from sum of impurities
    1after extrusion, before storage
    2after storage, open dish, 4 weeks, 40° C., 75% rel. humidity
  • [0259]
    In case of maleinic and fumaric acid these compounds and for maleinic acid another related compound were detected during the purity tests as impurities (up to about 40%). Their values have been subtracted from the sum of impurities
  • [0260]
    It becomes evident from a comparison of examples J1 and J2 to A1 and B1 that the presence of maleinic and fumaric acid protected oxymorphone totally against oxidation to N-oxide and to a large extent against other degradation although the samples were stored in open dishes and not in closed bottles. These results are comparable to those obtained with citric acid (example 1, D4 and E2-E4). Samples containing NaH2PO4 (J3) exhibited protection against N-oxide formation and other degradation when compared to the formulations without any acidic compound (A1 and B1) but to a less extent than the multicarboxylic acids like citric, maleinic and fumaric acid.
  • EXAMPLE 9
  • [0261]
    In order to investigate if the presence of citric acid also protects oxidation sensitive opioids other than oxymorphone against N-oxidation, tablets containing oxycodone hydrochloride were manufactured as described in example 1.
  • [0262]
    For comparison, also tablets containing smaller amounts of α-tocopherol were manufactured. The samples were stored in open dishes at 40° C. and 75% relative humidity for 4 weeks.
  • [0263]
    The individual constituents of the extruded mixtures as well as the total amount of decomposition products before and after storage under accelerated storage conditions are summarized in the table here below:
  • [0000]
    constituents (wt.-%) further decomposition products (wt.-%)
    ex. (A) PEO PEG HPMC α-toc. ingredient (wt.-%) oNo1 oNo2 Σ1 Σ2
    K1 1.5 77.0 10.0 10.0 1.5 / 0.05 0.58 0.31 1.63
    K2 1.5 78.3 10.0 10.0 0.2 / 0.05 0.28 0.58 0.69
    K3 1.5 76.0 10.0 10.0 1.5 Citric acid 1.0 nd nd 0.19 0.22
    K4 1.5 77.3 10.0 10.0 0.2 Citric acid 1.0 nd nd 0.18 0.23
    (A): oxycodone hydrochloride
    PEO: polyethylene oxide Mw 7 mio g/mol
    PEG: polyethylene glycol 6000
    HPMC: hypromellose 100,000 Pa*s
    α-toc.: α-tocopherol
    oNo: oxycodone-N-oxide
    Σ: sum of all impurities
    1after extrusion, before storage
    2after storage, open dish, 4 weeks, 40° C., 75% rel. humidity
  • [0264]
    These results show that citric acid protected oxycodone totally against oxidation to the N-oxide and to a large extent against other degradation although the samples were stored in open dishes rather than in closed bottles. Reducing the amount of α-tocopherol resulted in reduced degradation, when formulations were employed not containing citric acid. These results are comparable to those obtained with oxymorphone.

Claims (16)

  1. 1. A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N and comprising
    an opioid (A),
    a free physiologically acceptable acid (B) in an amount of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and
    a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.
  2. 2. The pharmaceutical dosage form according to claim 1, wherein the acid (B) is a multicarboxylic acid.
  3. 3. The pharmaceutical dosage form according to claim 2, wherein the multicarboxylic acid is selected from the group consisting of maleic acid, fumaric acid, glutaric acid, malonic acid and citric acid.
  4. 4. The pharmaceutical dosage form according to claim 1, wherein the content of the acid (B) is within the range of from 0.005 to 2.5 wt.-%, based on the total weight of the pharmaceutical dosage form.
  5. 5. The pharmaceutical dosage form according to claim 1, which comprises a polyalkylene glycol, wherein the relative weight ratio of the polyalkylene oxide to the polyalkylene glycol is within the range of 4.2±2:1.
  6. 6. The pharmaceutical dosage form according to claim 1, which comprises an antioxidant.
  7. 7. The pharmaceutical dosage form according to claim 6, wherein the antioxidant is α-tocopherol.
  8. 8. The pharmaceutical dosage form according to claim 6, wherein the content of the antioxidant is within the range of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form.
  9. 9. The pharmaceutical dosage form according to claim 1, wherein after storage for 4 weeks at 40° C. and 75% rel. humidity, the content of opioid (A) amounts to at least 98.0% of its original content before storage.
  10. 10. The pharmaceutical dosage form according to claim 1, wherein the opioid (A) is embedded in a matrix comprising the polyalkylene oxide (C), said matrix controlling the release of the opioid from the pharmaceutical dosage form.
  11. 11. The pharmaceutical dosage form according to claim 1, wherein the opioid (A) is selected from the group consisting of oxymorphone, oxycodone, hydromorphone, and the physiologically acceptable salts thereof.
  12. 12. The pharmaceutical dosage form according to claim 1, wherein the relative weight ratio of the polyalkylene oxide (C) and the opioid (A) is at least 1:1.
  13. 13. The pharmaceutical dosage form according to claim 1, which is adapted for administration once daily or twice daily.
  14. 14. The pharmaceutical dosage form according to claim 1, which has a breaking strength of at least 500 N.
  15. 15. A packaging containing the pharmaceutical dosage form of claim 1 and an oxygen scavenger.
  16. 16. The pharmaceutical dosage form according to claim 7, wherein the content of the antioxidant is within the range of from 0.001 to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form.
US12840471 2009-07-22 2010-07-21 Tamper-resistant dosage form for oxidation-sensitive opioids Pending US20110020451A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09009480.6 2009-07-22
EP09009480 2009-07-22

Publications (1)

Publication Number Publication Date
US20110020451A1 true true US20110020451A1 (en) 2011-01-27

Family

ID=41263602

Family Applications (4)

Application Number Title Priority Date Filing Date
US12840471 Pending US20110020451A1 (en) 2009-07-22 2010-07-21 Tamper-resistant dosage form for oxidation-sensitive opioids
US13343846 Abandoned US20120136021A1 (en) 2009-07-22 2012-01-05 Oxidation-stabilized tamper-resistant dosage form
US14192916 Abandoned US20140194455A1 (en) 2009-07-22 2014-02-28 Oxidation-stabilized tamper-resistant dosage form
US14841829 Active US9925146B2 (en) 2009-07-22 2015-09-01 Oxidation-stabilized tamper-resistant dosage form

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13343846 Abandoned US20120136021A1 (en) 2009-07-22 2012-01-05 Oxidation-stabilized tamper-resistant dosage form
US14192916 Abandoned US20140194455A1 (en) 2009-07-22 2014-02-28 Oxidation-stabilized tamper-resistant dosage form
US14841829 Active US9925146B2 (en) 2009-07-22 2015-09-01 Oxidation-stabilized tamper-resistant dosage form

Country Status (9)

Country Link
US (4) US20110020451A1 (en)
EP (4) EP2997965A1 (en)
JP (2) JP2012533585A (en)
KR (2) KR20120050975A (en)
CN (2) CN102639118B (en)
CA (2) CA2766172C (en)
ES (2) ES2560210T3 (en)
RU (2) RU2555531C2 (en)
WO (2) WO2011009603A8 (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060193782A1 (en) * 2003-08-06 2006-08-31 Johannes Bartholomaus Abuse-proofed dosage form
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20070183979A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20080311187A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US20080312264A1 (en) * 2004-07-01 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20080311197A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20090005408A1 (en) * 2003-12-24 2009-01-01 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20090052818A1 (en) * 2007-07-10 2009-02-26 Jason Matthew Mitmesser Hybrid bearing
US20090202634A1 (en) * 2008-01-25 2009-08-13 Grunenthal Gmbh Pharmaceutical dosage form
US20100015222A1 (en) * 2008-03-11 2010-01-21 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100196474A1 (en) * 2008-03-11 2010-08-05 Depomed, Inc. Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US20130225625A1 (en) * 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20140017310A1 (en) * 2012-07-12 2014-01-16 Mallinckrodt Llc Extended Release, Abuse Deterrent Pharmaceutical Compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US20140262883A1 (en) * 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9301918B2 (en) 2013-03-15 2016-04-05 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9522119B2 (en) 2014-07-15 2016-12-20 Isa Odidi Compositions and methods for reducing overdose
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2017070566A1 (en) * 2015-10-23 2017-04-27 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946870A (en) 2010-05-10 2013-02-27 欧洲凯尔特公司 Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012028319A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US20130090349A1 (en) * 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
CN104428002B (en) 2012-05-11 2017-08-11 格吕伦塔尔有限公司 Thermoformed tamper resistant pharmaceutical dosage form containing zinc
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
CA2983648A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
WO2016170094A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
EP3285748A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from different particles

Citations (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US4200704A (en) * 1978-09-28 1980-04-29 Union Carbide Corporation Controlled degradation of poly(ethylene oxide)
US4262017A (en) * 1978-05-22 1981-04-14 Basf Aktiengesellschaft Preparation of a vitamin E dry powder
US4427778A (en) * 1982-06-29 1984-01-24 Biochem Technology, Inc. Enzymatic preparation of particulate cellulose for tablet making
US4667013A (en) * 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US5126151A (en) * 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5387420A (en) * 1988-08-26 1995-02-07 May & Baker Ltd. Morphine-containing efferverscent composition
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
US5620697A (en) * 1992-12-31 1997-04-15 Orion-Yhtyma Oy Method for preparing matrix-type pharmaceutical compositions through ultrasonic means to accomplish melting
US5679685A (en) * 1993-12-22 1997-10-21 Ergo Science, Incorporated Accelerated release composition containing bromocriptine
US5707636A (en) * 1994-08-03 1998-01-13 Saitec S.R.L. Apparatus and method for preparing solid forms with controlled release of the active ingredient
US5741519A (en) * 1995-03-21 1998-04-21 Basf Aktiengesellschaft The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6051253A (en) * 1996-07-23 2000-04-18 Basf Aktiengesellschaft Production of solid drug forms
US6183781B1 (en) * 1996-05-14 2001-02-06 Alkermes Controlled Therapeutics, Inc. Method for fabricating polymer-based controlled-release devices
US6337319B1 (en) * 1995-08-18 2002-01-08 Wuyi Wang μ-Selective opioid peptides
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6387995B1 (en) * 1994-10-24 2002-05-14 Amcol International Corporation Precipitation polymerization process for producing an oil adsorbent polymer capable of entrapping solid particles and liquids and the product thereof
US6399100B1 (en) * 1997-08-01 2002-06-04 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
US20030008409A1 (en) * 2001-07-03 2003-01-09 Spearman Steven R. Method and apparatus for determining sunlight exposure
US20030064099A1 (en) * 2001-08-06 2003-04-03 Benjamin Oshlack Pharmaceutical formulation containing bittering agent
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030068370A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing irritant
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US6547977B1 (en) * 1998-04-02 2003-04-15 Applied Materials Inc. Method for etching low k dielectrics
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6569506B1 (en) * 1998-08-27 2003-05-27 Chevron Chemical Company Llc Oxygen scavenging packaging
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US20030104053A1 (en) * 2001-10-25 2003-06-05 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20040081694A1 (en) * 1994-11-04 2004-04-29 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6753009B2 (en) * 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US20050095291A1 (en) * 2000-02-08 2005-05-05 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060004034A1 (en) * 2002-11-11 2006-01-05 Gruenenthal Gmbh Spirocyclic cyclohexane compounds
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US20060012701A1 (en) * 2004-07-19 2006-01-19 Samsung Electronics Co., Ltd. Auto-stabilization method in control of driving image pickup device and reading memory and photographing apparatus having the same
US20060017916A1 (en) * 2004-06-09 2006-01-26 Clarke Allan J Apparatus for producing a pharmaceutical product
US20060073102A1 (en) * 2002-05-13 2006-04-06 Huaihung Kao D Abuse-resistant opioid solid dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20070065365A1 (en) * 2004-04-21 2007-03-22 Gruenenthal Gmbh Abuse-resistant transdermal system
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US7214385B2 (en) * 2001-08-06 2007-05-08 Thomas J. Gruber Pharmaceutical formulation containing dye
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20080081290A1 (en) * 2006-09-25 2008-04-03 Fujifilm Corporation Resist composition, resin for use in the resist composition, compound for use in the synthesis of the resin, and pattern-forming method using the resist composition
US20080131503A1 (en) * 2005-02-10 2008-06-05 Per Holm Stable Pharmaceutical Composition Comprising a Fixed Dose Combination of Fenofibrate and an Hmg-Coa Reductase Inhibitor
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US20090011016A1 (en) * 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US20090017121A1 (en) * 2001-10-25 2009-01-15 Bret Berner Gastric retained gabapentin dosage form
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090318395A1 (en) * 2006-12-22 2009-12-24 Grunenthal Gmbh 3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases
US7647800B2 (en) * 2004-07-30 2010-01-19 Snecma Shot, devices, and installations for ultrasonic peening, and parts treated thereby
US7674799B2 (en) * 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20100092553A1 (en) * 2005-11-10 2010-04-15 Flamel Technologies anti-misuse microparticulate oral pharmaceutical form
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
US20100098758A1 (en) * 2002-10-25 2010-04-22 Gruenenthal Gmbh Abuse-Resistant Dosage Form
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US20110038930A1 (en) * 2009-07-22 2011-02-17 Grunenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20110092515A1 (en) * 2008-07-03 2011-04-21 Zhihui Qiu Melt granulation process
US7939543B2 (en) * 2005-03-04 2011-05-10 Purdue Pharma L.P. Method of reducing α, β unsaturated ketones in opioid compositions
US20110129535A1 (en) * 2009-12-01 2011-06-02 Noven Pharmaceuticals, Inc. Transdermal testosterone device and delivery
US20120034171A1 (en) * 2003-08-06 2012-02-09 Gruenenthal Gmbh Abuse-proofed dosage form
US20120059065A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20120065220A1 (en) * 2010-09-02 2012-03-15 Grunenthal Gmbh Tamper Resistant Dosage Form Comprising An Anionic Polymer
US8144838B2 (en) * 1995-09-15 2012-03-27 At&T Intellectual Property Ii, L.P. Automated task classification system
US20120135071A1 (en) * 2002-06-17 2012-05-31 Grunenthal Gmbh Abuse-proofed dosage form
US20120136021A1 (en) * 2009-07-22 2012-05-31 Grunenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
US20130028970A1 (en) * 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US8383152B2 (en) * 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20130090349A1 (en) * 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
US20130129826A1 (en) * 2011-11-17 2013-05-23 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
US20140186440A1 (en) * 2008-03-11 2014-07-03 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20150079150A1 (en) * 2003-03-26 2015-03-19 Egalet Ltd. Morphine controlled release system

Family Cites Families (426)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA722109A (en) 1965-11-23 W. Mock Henry Extrusion of ethylene oxide polymers
US2524855A (en) 1950-10-10 Process for the manufacture of
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3370035A (en) 1961-06-23 1968-02-20 Takeda Chemical Industries Ltd Stabilization of polyalkylene oxide
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
GB1147210A (en) 1965-06-30 1969-04-02 Eastman Kodak Co Improvements in or relating to vitamins
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US3806603A (en) 1969-10-13 1974-04-23 W Gaunt Pharmaceutical carriers of plasticized dried milled particles of hydrated cooked rice endosperm
DE2210071A1 (en) 1971-03-09 1972-09-14
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3966747A (en) 1972-10-26 1976-06-29 Bristol-Myers Company 9-Hydroxy-6,7-benzomorphans
US4014965A (en) 1972-11-24 1977-03-29 The Dow Chemical Company Process for scrapless forming of plastic articles
US3941865A (en) 1973-12-10 1976-03-02 Union Carbide Corporation Extrusion of ethylene oxide resins
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
DE2530563C2 (en) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen, De
JPS603286B2 (en) 1977-03-03 1985-01-26 Nippon Kayaku Kk
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4175119A (en) 1978-01-11 1979-11-20 Porter Garry L Composition and method to prevent accidental and intentional overdosage with psychoactive drugs
US4211681A (en) 1978-08-16 1980-07-08 Union Carbide Corporation Poly(ethylene oxide) compositions
FI793235A (en) 1978-10-19 1980-04-20 Mallinckrodt Inc Foerfarande Foer framstaellning of oxomorfon
US4258027A (en) 1979-03-26 1981-03-24 Mead Johnson & Company Multi-fractionable tablet structure
US4215104A (en) 1979-03-26 1980-07-29 Mead Johnson & Company Multi-fractionable tablet structure
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
BE884760A (en) 1979-08-16 1981-02-13 Ciba Geigy scored tablet allowing a controlled release and delayed active substance
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
JPH0129764B2 (en) 1980-06-03 1989-06-14 Kissei Pharmaceutical
DE3024416C2 (en) 1980-06-28 1982-04-15 Goedecke Ag, 1000 Berlin, De
US4473640A (en) 1982-06-03 1984-09-25 Combie Joan D Detection of morphine and its analogues using enzymatic hydrolysis
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4485211A (en) 1982-09-15 1984-11-27 The B. F. Goodrich Company Poly(glycidyl ether)block copolymers and process for their preparation
US4427681A (en) 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
DE3246436A1 (en) 1982-12-15 1984-06-20 Alfred Rey Liegeflaeche with solarium-irradiation
US4529583A (en) 1983-03-07 1985-07-16 Clear Lake Development Group Composition and method of immobilizing emetics and method of treating human beings with emetics
US4603143A (en) 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
DK450985D0 (en) 1984-10-09 1985-10-03 Dow Chemical Co Dosage form maintained release preparations, based on highly plasticized celluloseethergeler
GB8507779D0 (en) 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
WO1987000045A1 (en) 1985-06-24 1987-01-15 Ici Australia Limited Ingestible capsules
EP0328775B1 (en) 1985-06-28 1993-10-20 Carrington Laboratories, Inc. Processes for preparation of aloe products, products produced thereby and compositions thereof
US4992279A (en) 1985-07-03 1991-02-12 Kraft General Foods, Inc. Sweetness inhibitor
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0226061B1 (en) 1985-12-17 1994-02-16 United States Surgical Corporation High molecular weight bioresorbable polymers and implantation devices thereof
US5229164A (en) 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
US4711894A (en) 1986-01-16 1987-12-08 Henkel Corporation Stabilized tocopherol in dry, particulate, free-flowing form
US5198226A (en) 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
EP0239973A3 (en) 1986-03-31 1989-11-08 Union Carbide Corporation Catalyst and process for alkylene oxide polymerization
DE3612211A1 (en) 1986-04-11 1987-10-15 Basf Ag Continuous method for tableting
USRE33093E (en) 1986-06-16 1989-10-17 Johnson & Johnson Consumer Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
USRE34990E (en) 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CA1335748C (en) 1986-09-25 1995-05-30 Jeffrey Lawrence Finnan Crosslinked gelatins
US5227157A (en) 1986-10-14 1993-07-13 Board Of Regents, The University Of Texas System Delivery of therapeutic agents
EP0277289B8 (en) 1986-11-10 2003-05-21 Biopure Corporation Extra pure semi-synthetic blood substitute
JPH0831303B2 (en) 1986-12-01 1996-03-27 オムロン株式会社 Chip type pigweed -'s
EP0277092B1 (en) 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutic system for slightly soluble active ingredients
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5051261A (en) 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
DE3877971D1 (en) 1987-12-17 1993-03-11 Upjohn Co Triple notched drug tablet.
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag A process for preparing pharmaceutical mixtures
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
JPH0249719A (en) 1988-08-11 1990-02-20 Dai Ichi Kogyo Seiyaku Co Ltd Oil soluble-vitamin powder having readily water-dispersible and soluble performance
DE3830353A1 (en) 1988-09-07 1990-03-15 Basf Ag shaping process for the continuous preparation of solid pharmaceutical
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5139790A (en) 1988-10-14 1992-08-18 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US4957668A (en) 1988-12-07 1990-09-18 General Motors Corporation Ultrasonic compacting and bonding particles
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5200197A (en) 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
EP0449775A3 (en) 1990-03-29 1992-09-02 Ciba-Geigy Ag Polyether-polyester block copolymers and their use as dispersing agents
FR2664851B1 (en) 1990-07-20 1992-10-16 Oreal Method for compacting a powder mixture to obtain an absorbent or partially friable compact product and product obtained by this process.
US5125151A (en) 1990-08-08 1992-06-30 Emhart Inc. Rivet setting tool
EP0477135A1 (en) 1990-09-07 1992-03-25 Warner-Lambert Company Chewable spheroidal coated microcapsules and methods for preparing same
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP3073054B2 (en) 1991-07-11 2000-08-07 住友精化株式会社 Manufacturing method of the alkylene oxide polymer
DE69231856D1 (en) 1991-08-30 2001-07-05 Showa Pharm Chem Ind dry gel composition
WO1993006723A1 (en) 1991-10-04 1993-04-15 Olin Corporation Fungicide tablet
DE4138513A1 (en) 1991-11-23 1993-05-27 Basf Ag A solid pharmaceutical sustained-release form
CA2125148C (en) 1991-12-05 1999-05-11 Siva N. Raman A carbohydrate glass matrix for the sustained release of a therapeutic agent
DK0617612T3 (en) 1991-12-18 1998-04-14 Warner Lambert Co A process for the preparation of a solid dispersion
WO1993023017A1 (en) 1992-05-06 1993-11-25 Janssen Pharmaceutica, Inc. Pharmaceutical and other dosage forms
DE59302200D1 (en) 1992-05-22 1996-05-15 Goedecke Ag A process for producing sustained-release drug preparations
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
DE4227385A1 (en) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh pancreatin
DE4229085C2 (en) 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated dividable tablet
JP3140465B2 (en) 1992-09-18 2001-03-05 山之内製薬株式会社 Hydrogel sustained-release preparation
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
FI101039B (en) 1992-10-09 1998-04-15 Eeva Kristoffersson Process for the preparation of drug pellets
DK0598606T3 (en) 1992-11-18 1999-11-22 Johnson & Johnson Consumer Extrudable compositions for topical transdermal delivery of drugs
DE69326163T2 (en) 1992-12-23 2000-05-04 Saitec Srl A process for the manufacturing of dosage forms and controlled release dosage forms and the thus obtained
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4309528C2 (en) 1993-03-24 1998-05-20 Doxa Gmbh Film or film tubing from casein, process for their preparation and their use
US5849240A (en) 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
EP0654263B1 (en) 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
ES2124372T5 (en) 1993-07-01 2004-07-16 Euro-Celtique S.A. Sustained release compositions containing morphine.
DE4329794C2 (en) 1993-09-03 1997-09-18 Gruenenthal Gmbh Medicines containing tramadol sustained release
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
EP2036558A3 (en) 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
WO1995017174A1 (en) 1993-12-20 1995-06-29 The Procter & Gamble Company Process for making laxatives containing dioctyl sulfosuccinate
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
DE69530973T2 (en) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park A process for preparing finely divided pharmaceutical formulations
US5458887A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
DE4413350A1 (en) 1994-04-18 1995-10-19 Basf Ag Slow-release matrix pellets, and methods for their preparation
RU2130311C1 (en) 1994-05-06 1999-05-20 Пфайзер Инк. Medicinal controlled-releasing forms of azithromycin
ES2132589T3 (en) 1994-05-18 1999-08-16 Lannacher Heilmittel Preparation oral delayed effect.
US5460826A (en) 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
DE4426245A1 (en) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds having pharmacological activity
USRE39593E1 (en) 1994-07-23 2007-04-24 Gruenenthal Gmbh 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
JPH0851331A (en) 1994-08-04 1996-02-20 Asahi Kasei Micro Syst Kk Automatic gain control circuit
WO1996012466A1 (en) 1994-10-25 1996-05-02 Daratech Pty. Ltd. Controlled release container with core and outer shell
DE4446470A1 (en) 1994-12-23 1996-06-27 Basf Ag A process for the production of divisible tablets
DE19504832A1 (en) 1995-02-14 1996-08-22 Basf Ag Solid drug preparations
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6117453A (en) 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US5900425A (en) 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
DE19522899C1 (en) 1995-06-23 1996-12-19 Hexal Pharmaforschung Gmbh Process for the continuous sintering of granules
US5759583A (en) 1995-08-30 1998-06-02 Syntex (U.S.A.) Inc. Sustained release poly (lactic/glycolic) matrices
US6063405A (en) 1995-09-29 2000-05-16 L.A.M. Pharmaceuticals, Llc Sustained release delivery system
US5811126A (en) 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
DE19539361A1 (en) 1995-10-23 1997-04-24 Basf Ag A process for producing multilayer, solid drug forms for oral or rectal administration
WO1997018714A1 (en) 1995-11-22 1997-05-29 The Minister Of Agriculture Fisheries & Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Alkylphosphines as pesticidal agents
DE19547766A1 (en) 1995-12-20 1997-06-26 Gruenenthal Gmbh 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
EP0914097B1 (en) 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
CA2577233C (en) 1996-04-05 2009-08-18 Takeda Pharmaceutical Company Limited Pharmaceutical composition containing angiotensin ii antagonist
US20020114838A1 (en) 1996-04-05 2002-08-22 Ayer Atul D. Uniform drug delivery therapy
EP0952824B1 (en) 1996-06-06 2004-09-29 Bifodan A/S Enteric coating, comprising alginic acid, for an oral preparation
EP2065055A1 (en) 1996-06-26 2009-06-03 Board of Regents, The University of Texas System Holt-melt extrudable pharmaceutical formulation
ES2322405T3 (en) 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matrix controlled to high doses insoluble drugs release.
NL1003684C2 (en) 1996-07-25 1998-01-28 Weterings B V H A device for dispensing a liquid.
DE19630236A1 (en) 1996-07-26 1998-01-29 Wolff Walsrode Ag Biaxially stretched, biodegradable and compostable sausage casing
DE69731114D1 (en) 1996-11-05 2004-11-11 Novamont Spa contain Biologiscgh abbaure polymer compositions, starch and a thermoplastic polymer
US5991799A (en) 1996-12-20 1999-11-23 Liberate Technologies Information retrieval system using an internet multiplexer to focus user selection
DE19705538C1 (en) 1997-02-14 1998-08-27 Goedecke Ag Process for the separation of active ingredients in solid pharmaceutical preparations
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
DE19710008A1 (en) 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase preparation forms of an opioid sustained release Analgeticums
DE19710009A1 (en) 1997-03-12 1998-09-24 Knoll Ag Multi-phase active ingredient-containing formulations
DE19710213A1 (en) 1997-03-12 1998-09-17 Basf Ag A process for producing solid combination drug forms
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6139770A (en) * 1997-05-16 2000-10-31 Chevron Chemical Company Llc Photoinitiators and oxygen scavenging compositions
DE19721467A1 (en) 1997-05-22 1998-11-26 Basf Ag A process for preparing small-scale preparations of biologically active substances
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (en) 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for sustained release of drugs highly soluble
WO1999001111A1 (en) 1997-07-02 1999-01-14 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
JP2003525828A (en) 1997-09-10 2003-09-02 アライドシグナル インコーポレイテッド Injection molding by a wet method structural materials based on zirconia
US6009390A (en) 1997-09-11 1999-12-28 Lucent Technologies Inc. Technique for selective use of Gaussian kernels and mixture component weights of tied-mixture hidden Markov models for speech recognition
ES2174538T3 (en) 1997-11-28 2002-11-01 Knoll Ag Procedure for obtaining substances exempt solvent, noncrystalline, biologically active.
US6344535B1 (en) 1997-12-03 2002-02-05 Bayer Aktiengesellschaft Polyether ester amides
DE19753534A1 (en) 1997-12-03 1999-06-10 Bayer Ag Biodegradable thermoplastic polyester-amides with good mechanical properties for molding, film and fiber, useful for e.g. compostable refuse bag
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
DE19800698A1 (en) 1998-01-10 1999-07-15 Bayer Ag Biodegradable polyester with block-type structure polyester and polyamide segments
DE19800689C1 (en) 1998-01-10 1999-07-15 Deloro Stellite Gmbh Molding of a wear-resistant material
DE69918233D1 (en) 1998-03-05 2004-07-29 Mitsui Chemicals Inc composition polylactic acid and derived movie
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6090411A (en) 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6110500A (en) 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
DE19822979A1 (en) 1998-05-25 1999-12-02 Kalle Nalo Gmbh & Co Kg Film with starch or starch derivatives and polyester urethanes, as well as processes for their preparation
DE19841244A1 (en) 1998-09-09 2000-03-16 Knoll Ag Method and apparatus for the manufacture of tablets
US6268177B1 (en) 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase
CN1327384A (en) 1998-10-20 2001-12-19 韩国科学技术研究院 Bioflavonoids as plasma high density lipoprotein level increasing agent
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
ES2141688B1 (en) 1998-11-06 2001-02-01 Vita Invest Sa New esters derived from substituted phenyl-cyclohexyl compounds.
DE19855440A1 (en) 1998-12-01 2000-06-08 Basf Ag A method for producing solid dosage forms by melt extrusion
DE19856147A1 (en) 1998-12-04 2000-06-08 Knoll Ag Divisible solid dosage forms and methods for their preparation
EP1005863A1 (en) 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
WO2000040205A3 (en) 1999-01-05 2000-09-28 Shubha Chungi Sustained release formulation with reduced moisture sensitivity
KR20010034730A (en) 1999-02-04 2001-04-25 아키라 이가키 Arteriosclerosis-preventing material, immune-activating material, and vertebrate that has eaten such materials, and eggs thereof
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
CA2379987A1 (en) 1999-07-29 2001-02-08 Roxane Laboratories, Inc. Opioid sustained-released formulation
CA2387705C (en) 1999-08-04 2009-06-30 Yamanouchi Pharmaceutical Co., Ltd. Stable pharmaceutical composition for oral use
KR100345214B1 (en) 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
DE19940944B4 (en) 1999-08-31 2006-10-12 Grünenthal GmbH Sustained release, oral pharmaceutical forms of administration
EP1207866B1 (en) 1999-08-31 2004-10-13 Grünenthal GmbH Delayed-action form of administration containing tramadol saccharinate
DE19960494A1 (en) 1999-12-15 2001-06-21 Knoll Ag Apparatus and method for producing solid forms containing active substance
ES2160534B1 (en) 1999-12-30 2002-04-16 Vita Invest Sa New esters derived from (RR, SS) -2-hydroxybenzoate of 3- (2-dimethylaminomethyl-1-hydroxycyclohexyl) phenyl.
US6680070B1 (en) 2000-01-18 2004-01-20 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10015479A1 (en) 2000-03-29 2001-10-11 Basf Ag Solid oral dosage forms with delayed release of active ingredient and high mechanical stability
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6572887B2 (en) 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
JP5324732B2 (en) 2000-05-23 2013-10-23 スネス ファーマシューティカルズ インコーポレイテッド Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
DE10029201A1 (en) 2000-06-19 2001-12-20 Basf Ag Retarded release oral dosage form, obtained by granulating mixture containing active agent and polyvinyl acetate-polyvinyl pyrrolidone mixture below the melting temperature
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE10036400A1 (en) 2000-07-26 2002-06-06 Mitsubishi Polyester Film Gmbh White, biaxially oriented polyester film
US6883976B2 (en) 2001-07-30 2005-04-26 Seikoh Giken Co., Ltd. Optical fiber ferrule assembly and optical module and optical connector using the same
US6642205B2 (en) 2000-09-25 2003-11-04 Pro-Pharmaceuticals, Inc. Methods and compositions for reducing side effects in chemotherapeutic treatments
JP2004509908A (en) 2000-09-27 2004-04-02 ダニスコ エイ/エス Antibacterial agents
WO2002026928A1 (en) 2000-09-28 2002-04-04 The Dow Chemical Company Polymer composite structures useful for controlled release systems
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2002035991A3 (en) 2000-10-30 2002-08-01 Univ Texas Spherical particles produced by a hot-melt extrusion/spheronization process
JP2004512354A (en) 2000-10-30 2004-04-22 ユーロ−セルティーク,エス.エイ. Hydrocodone controlled-release formulation
JP2002265592A (en) 2001-03-07 2002-09-18 Sumitomo Seika Chem Co Ltd Process for producing alkylene oxide polymer
WO2002071860A1 (en) 2001-03-13 2002-09-19 L.A. Dreyfus Co. Gum base and gum manufacturing using particulated gum base ingredients
JP3967554B2 (en) 2001-03-15 2007-08-29 国立大学法人名古屋大学 Flavonoid compounds and a method of manufacturing the same
US20020132395A1 (en) * 2001-03-16 2002-09-19 International Business Machines Corporation Body contact in SOI devices by electrically weakening the oxide under the body
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
US20020187192A1 (en) 2001-04-30 2002-12-12 Yatindra Joshi Pharmaceutical composition which reduces or eliminates drug abuse potential
JP2004530748A (en) 2001-05-01 2004-10-07 ユニオン・カーバイド・ケミカルズ・アンド・プラスティックス・テクノロジー・コーポレイション Poly reducing the amount of formic acid compound (alkylene oxide)
DK2281555T3 (en) 2001-05-02 2016-06-06 Euro-Celtique S A Oxycodone for once daily administration
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US6623754B2 (en) 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US7125561B2 (en) 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
DE60223254D1 (en) 2001-07-06 2007-12-13 Penwest Pharmaceuticals Co The sustained release formulations of oxymorphone
EP1406630A1 (en) 2001-07-06 2004-04-14 Endo Pharmaceuticals Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
JP2003020517A (en) 2001-07-10 2003-01-24 Calp Corp Resin composition for compound fiber
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
EP1414413A1 (en) 2001-08-06 2004-05-06 Euro-Celtique S.A. Compositions and methods to prevent abuse of opioids
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030049272A1 (en) 2001-08-30 2003-03-13 Yatindra Joshi Pharmaceutical composition which produces irritation
US20030059467A1 (en) 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6691698B2 (en) 2001-09-14 2004-02-17 Fmc Technologies Inc. Cooking oven having curved heat exchanger
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
DK1429734T3 (en) 2001-09-21 2008-05-13 Egalet As Solid dispersions of carvedilol for the Controlled Release
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
WO2003028698A3 (en) 2001-09-26 2003-10-23 Klaus-Juergen Steffens Method and device for producing granulates that comprise at least one pharmaceutical active substance
JP2005523876A (en) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー Opioid formulations potential for abuse is reduced
EP1429724B1 (en) 2001-09-28 2013-11-06 McNeil-PPC, Inc. Dosage form containing a confectionery composition
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
DE60210317T2 (en) 2001-10-09 2006-12-21 The Procter & Gamble Company, Cincinnati Aqueous compositions for surface treatment
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
JP2003125706A (en) 2001-10-23 2003-05-07 Lion Corp Mouth freshening preparation
DK1439829T3 (en) 2001-10-24 2005-10-10 Gruenenthal Gmbh Medicament containing 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol with delayed release of the active substance
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030104052A1 (en) 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003037244A3 (en) 2001-10-29 2004-01-22 Therics Inc System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
CA2464528A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
EP1463515A4 (en) 2001-12-06 2005-01-12 Scolr Pharma Inc Isoflavone composition for oral delivery
FR2833838B1 (en) 2001-12-21 2005-09-16 Ellipse Pharmaceuticals Method of manufacturing a tablet including a morphine-like analgesic and compresses obtained
US7572750B2 (en) 2002-02-11 2009-08-11 University Of Wollongong Catalysts and processes for their preparation
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030190343A1 (en) 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
KR100717591B1 (en) 2002-04-05 2007-05-15 유로-셀띠끄 소시에떼 아노님 Matrix for sustained, invariant and independent release of active compounds
DE10217232B4 (en) 2002-04-18 2004-08-19 Ticona Gmbh A method for preparing filled granules of polyethylenes high or ultra-high molecular weight
US6960617B2 (en) 2002-04-22 2005-11-01 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
ES2320435T3 (en) 2002-04-29 2009-05-22 Alza Corporation Method and dosage forms for the controlled administration of oxycodone.
DE10250083A1 (en) 2002-06-17 2003-12-24 Gruenenthal Gmbh Abuse-proofed dosage form
US20040011806A1 (en) 2002-07-17 2004-01-22 Luciano Packaging Technologies, Inc. Tablet filler device with star wheel
US20070196481A1 (en) 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
WO2004017947A1 (en) 2002-08-21 2004-03-04 Phoqus Pharmaceuticals Limited Use of an aqueous solution of citric acid and a water-soluble sugar like lactitol as granulation liquid in the manufacture of tablets
US7388068B2 (en) 2002-08-21 2008-06-17 Clariant Produkte (Deutschland) Gmbh Copolymers made of alkylene oxides and glycidyl ethers and use thereof as polymerizable emulsifiers
CN100415233C (en) * 2002-09-17 2008-09-03 惠氏公司 Oral formulations
WO2004026263A3 (en) 2002-09-20 2004-07-01 Fmc Corp Cosmetic composition containing microcrystalline cellulose
WO2004026308A1 (en) 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
WO2004026262A3 (en) 2002-09-23 2004-06-10 Verion Inc Abuse-resistant pharmaceutical compositions
DE10250087A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
DE10250088A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
JP2006507277A (en) 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド 24 hours effective sustained-release tramadol formulation
DE10250084A1 (en) 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE602004025159D1 (en) 2003-03-26 2010-03-04 Egalet As Matrix preparations for the controlled administration of drugs
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
DK1615646T3 (en) * 2003-04-08 2015-02-02 Progenics Pharm Inc Pharmaceutical formulations containing methylnaltrexone
CA2519556C (en) 2003-04-21 2011-01-18 Benjamin Oshlack Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
ES2341546T3 (en) 2003-04-21 2010-06-22 Euro-Celtique S.A. tamper resistant opioid for delivery products.
CA2522529C (en) 2003-04-30 2015-10-20 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CN1473562A (en) 2003-06-27 2004-02-11 辉 刘 Mouth cavity quick dissolving quick disintegrating freeze-dried tablet and its preparing method
US20050015730A1 (en) 2003-07-14 2005-01-20 Srimanth Gunturi Systems, methods and computer program products for identifying tab order sequence of graphically represented elements
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
RU2339365C2 (en) 2003-08-06 2008-11-27 Грюненталь Гмбх Drug dosage form, protected from unintended application
DK1842533T3 (en) 2003-08-06 2013-05-27 Gruenenthal Gmbh Dosage protected against abuse
US20050063214A1 (en) 2003-09-22 2005-03-24 Daisaburo Takashima Semiconductor integrated circuit device
CA2539027C (en) 2003-09-25 2010-02-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
KR20060097008A (en) 2003-09-30 2006-09-13 알자 코포레이션 Osmotically driven active agent delivery device providing an ascending release profile
US20060172006A1 (en) 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
RU2006118323A (en) 2003-10-29 2007-12-10 Алза Корпорейшн (Us) Dosage forms with controlled release of oxycodone for a single oral administration
ES2600577T3 (en) 2003-12-04 2017-02-09 Bend Research, Inc. Spray-solidification method using an extruder to prepare compositions in multiparticulate crystalline drugs
DE602004005076T2 (en) 2003-12-09 2007-11-15 Euro-Celtique S.A. Co-extruded safety dosage form manufacturing processes with an active ingredient and an adverse agent and for
WO2005060942A1 (en) 2003-12-19 2005-07-07 Aurobindo Pharma Ltd Extended release pharmaceutical composition of metformin
DE10360792A1 (en) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclic cyclohexane derivatives
WO2005065646A3 (en) 2003-12-29 2005-12-08 Alza Corp Inc Novel drug compositions and dosage forms
WO2005079752A3 (en) 2004-02-11 2006-12-14 Rubicon Res Private Ltd Controlled release pharmaceutical compositions with improved bioavailability
EP3228308A1 (en) 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
GB0403100D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Particulates
WO2005079760A1 (en) 2004-02-12 2005-09-01 Euro-Celtique S.A. Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
KR100789227B1 (en) 2004-02-23 2008-01-02 유로-셀띠끄 소시에떼 아노님 Abuse resistance opioid transdermal delivery device
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
WO2005102286A1 (en) 2004-04-22 2005-11-03 Grünenthal GmbH Method for the production of an abuse-proof, solid form of administration
DE102004020220A1 (en) 2004-04-22 2005-11-10 Grünenthal GmbH A process for preparing a secured against misuse, solid dosage form
WO2005105036A1 (en) 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
DE602004007905T2 (en) 2004-06-28 2008-05-08 Grünenthal GmbH Crystalline forms of (-) - (1R, 2R) -3- (3-dimethylamino-1-ethyl-2-methylpropyl) -phenol hydrochloride
US20060003010A1 (en) 2004-06-30 2006-01-05 Ibsa Institut Biochimique S.A. Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction and processes for obtaining the same
DE102004032103A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Abuse-proofed, oral dosage form
JP5700904B2 (en) 2004-07-01 2015-04-15 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング (1r, 2r) -3- (3- Dimethylamino-1-ethyl-2-methyl-propyl) - abuse prevention oral dosage forms containing phenol
JP5259183B2 (en) 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Protected oral dosage form against abuse
EP1765298B1 (en) 2004-07-01 2012-10-24 Gruenenthal Gmbh Method for producing a solid dosage form, which is safeguarded against abuse, while using a planetary gear extruder
JP2008508201A (en) 2004-07-27 2008-03-21 ユニリーバー・ナームローゼ・ベンノートシヤープ Hair care composition
US20060068009A1 (en) 2004-09-30 2006-03-30 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20070077297A1 (en) 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
ES2630002T3 (en) 2005-01-26 2017-08-17 Taiho Pharmaceutical Co., Ltd. anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH A process for preparing a secured against misuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Unbreakable dosage forms with delayed release
US20060194759A1 (en) 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US7732427B2 (en) 2005-03-31 2010-06-08 University Of Delaware Multifunctional and biologically active matrices from multicomponent polymeric solutions
WO2006105615A1 (en) 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
CN102552162A (en) 2005-05-10 2012-07-11 诺瓦提斯公司 Extrusion process for making compositions with poorly compressible therapeutic compounds
CA2611081C (en) 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
WO2007005716A3 (en) 2005-06-30 2007-11-22 Najib Babul Methods of treatment and compositions for use thereof
RU2008104638A (en) 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) The pharmaceutical compositions are well soluble in water medicaments that ensure their slow release
US8858993B2 (en) 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1909760A1 (en) 2005-08-03 2008-04-16 Eastman Chemical Company Tocopheryl polyethylene glycol succinate powder and process for preparing same
WO2007043710A9 (en) 2005-10-14 2007-06-07 Kitasato Inst Novel dihydropseudoerythromycin derivatives
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
DE202006014131U1 (en) 2005-10-31 2007-01-04 Alza Corp., Mountain View Oral dosage form useful for treating pain comprises an opioid and a dosing structure that provides extended release of the opioid in the presence of alcohol
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
FR2892937B1 (en) 2005-11-10 2013-04-05 Flamel Tech Sa microparticulate oral pharmaceutical form anti-misuse
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
RU2433817C2 (en) 2006-01-21 2011-11-20 Эбботт Гмбх Унд Ко.Кг Medical form and method for delivery of habit-forming medical substances
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP1994034B1 (en) 2006-03-02 2009-11-11 Mallinckrodt, Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
US20100226855A1 (en) 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
CA2647809C (en) 2006-03-24 2016-08-16 Auxilium Pharmaceuticals, Inc. Stabilized compositions containing alkaline labile drugs
US20070224637A1 (en) 2006-03-24 2007-09-27 Mcauliffe Joseph C Oxidative protection of lipid layer biosensors
US8465759B2 (en) * 2006-03-24 2013-06-18 Auxilium Us Holdings, Llc Process for the preparation of a hot-melt extruded laminate
US20140010860A1 (en) 2006-05-12 2014-01-09 Isa Odidi Abuse and alcohol resistant drug composition
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
CN101091721A (en) 2006-06-22 2007-12-26 孙明 Method for preparing new type asshide
JP4029109B1 (en) 2006-07-18 2008-01-09 タマ生化学株式会社 The composite powder and a method of manufacturing vitamin e and proline
EP2292229B1 (en) 2006-08-25 2012-05-23 Purdue Pharma LP Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
JP5730572B2 (en) 2007-09-13 2015-06-10 シマ ラブス インク. Abuse-resistant formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
GB0624880D0 (en) 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
CA2674536C (en) 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008094877A3 (en) 2007-01-30 2008-10-30 Drugtech Corp Compositions for oral delivery of pharmaceuticals
CN100579525C (en) 2007-02-02 2010-01-13 东南大学 Sustained release preparation of licardipine hydrochloride and its preparing process
CN101057849A (en) 2007-02-27 2007-10-24 齐齐哈尔医学院 Slow-releasing preparation containing metformin hydrochloride and glipizide and its preparation method
CA2678367C (en) 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
EP1980245A1 (en) 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
CA2685118C (en) 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US20110020408A1 (en) 2007-05-17 2011-01-27 Ranbaxy Laboratories Limited multilayered modified release formulation comprising amoxicillin and clavulanate
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
CA2690956C (en) 2007-07-01 2017-01-03 Joseph Peter Habboushe Combination tablet with chewable outer layer
KR20100055431A (en) 2007-07-20 2010-05-26 애보트 게엠베하 운트 콤파니 카게 Formulations of nonopioid and confined opioid analgesics
EP2200591A2 (en) 2007-09-11 2010-06-30 Ranbaxy Laboratories Limited Controlled release pharmaceutical dosage forms of trimetazidine
WO2009051819A1 (en) 2007-10-17 2009-04-23 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and thermoplastic extrusion processes for producing such systems
CN104958282A (en) 2007-11-23 2015-10-07 格吕伦塔尔有限公司 Tapentadol compositions
JP2011506319A (en) 2007-12-06 2011-03-03 デュレクト コーポレーション Pain, methods useful in the treatment of inflammation associated with an arthritic condition or chronic disease,
EP2229151B1 (en) 2007-12-12 2012-08-08 Basf Se Salts of active ingredients with polymeric counter-ions
RU2010129907A (en) 2007-12-17 2012-01-27 Лабофарм Инк. (CA) Pharmaceutical form with controlled release, preventing the misuse of
KR100970665B1 (en) 2008-02-04 2010-07-15 삼일제약주식회사 Sustained release tablet containing alfuzosin or its salt
JP2011513391A (en) 2008-03-05 2011-04-28 パナセア バイオテック リミテッド Sustained release pharmaceutical compositions containing mycophenolate AND METHOD
CA2734646C (en) 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates
WO2010057036A3 (en) 2008-11-14 2011-06-09 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
WO2010066034A8 (en) 2008-12-12 2010-08-19 Paladin Labs Inc. Narcotic drug formulations with decreased abuse potential
EP2367541B1 (en) 2008-12-16 2014-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CA2750400A1 (en) 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
WO2010088911A1 (en) 2009-02-06 2010-08-12 Egalet A/S Pharmaceutical compositions resistant to abuse
EP2408436B1 (en) 2009-03-18 2017-02-22 Evonik Röhm GmbH Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
EP2246063A1 (en) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
WO2010149169A3 (en) 2009-06-24 2011-06-16 Egalet A/S Controlled release formulations
WO2011008298A3 (en) 2009-07-16 2011-06-16 Nectid, Inc. Novel axomadol dosage forms
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
CN102821757B (en) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 Preparation of a powdered pharmaceutical composition by an extruder
US20110223244A1 (en) 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
JP2013523780A (en) 2010-04-02 2013-06-17 オールトランツ インコーポレイティド Opiate agonists and agonists - abuse deterrent transdermal formulation of the antagonist
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
EP2560624A4 (en) 2010-04-23 2014-06-25 Subhash Desai Therapeutic formulation for reduced drug side effects
FR2960775A1 (en) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistant to diversion
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US20120321716A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for preventing abuse of solid dosage forms
EP3287123A1 (en) 2011-03-04 2018-02-28 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20120328697A1 (en) 2011-06-01 2012-12-27 Fmc Corporation Controlled Release Solid Dose Forms
US20140127300A1 (en) 2011-06-30 2014-05-08 Neos Therapeutics, Lp Abuse resistant drug forms
KR20140053158A (en) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 Tamper-resistant tablet providing immediate drug release
FR2979242A1 (en) 2011-08-29 2013-03-01 Sanofi Sa Compresses against misuse, has basic paracetamol and oxycodone
JP6144274B2 (en) 2011-12-09 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ Poly (epsilon - caprolactone) and pharmaceutical dosage forms containing polyethylene oxide
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
EP3170492A1 (en) 2012-03-02 2017-05-24 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
CN104394851B (en) 2012-04-18 2017-12-01 格吕伦塔尔有限公司 Dose anti-tampering and anti - dumping pharmaceutical dosage forms
CN104428002B (en) 2012-05-11 2017-08-11 格吕伦塔尔有限公司 Thermoformed tamper resistant pharmaceutical dosage form containing zinc
US20130303623A1 (en) 2012-05-11 2013-11-14 Grünenthal GmbH Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014059512A1 (en) 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
EP2968169A1 (en) 2013-03-15 2016-01-20 Mallinckrodt LLC Compositions comprising an opioid and an additional active pharmaceutical ingredient for rapid onset and extended duration of analgesia that may be administered without regard to food
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3003279A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
CA2817728A1 (en) 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
CA2917136A1 (en) 2013-07-12 2015-01-15 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015103379A1 (en) 2013-12-31 2015-07-09 Kashiv Pharma, Llc Abuse-resistant drug formulations

Patent Citations (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US4262017A (en) * 1978-05-22 1981-04-14 Basf Aktiengesellschaft Preparation of a vitamin E dry powder
US4200704A (en) * 1978-09-28 1980-04-29 Union Carbide Corporation Controlled degradation of poly(ethylene oxide)
US4427778A (en) * 1982-06-29 1984-01-24 Biochem Technology, Inc. Enzymatic preparation of particulate cellulose for tablet making
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4667013A (en) * 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
US4892889A (en) * 1986-11-18 1990-01-09 Basf Corporation Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin
US4954346A (en) * 1988-06-08 1990-09-04 Ciba-Geigy Corporation Orally administrable nifedipine solution in a solid light resistant dosage form
US5387420A (en) * 1988-08-26 1995-02-07 May & Baker Ltd. Morphine-containing efferverscent composition
US5190760A (en) * 1989-07-08 1993-03-02 Coopers Animal Health Limited Solid pharmaceutical composition
US5126151A (en) * 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
US5593694A (en) * 1991-10-04 1997-01-14 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release tablet
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5620697A (en) * 1992-12-31 1997-04-15 Orion-Yhtyma Oy Method for preparing matrix-type pharmaceutical compositions through ultrasonic means to accomplish melting
US20090117191A1 (en) * 1993-05-10 2009-05-07 Purdue Pharma Products L.P. Controlled release tramadol formulations
US5591452A (en) * 1993-05-10 1997-01-07 Euro-Celtique, S.A. Controlled release formulation
US5679685A (en) * 1993-12-22 1997-10-21 Ergo Science, Incorporated Accelerated release composition containing bromocriptine
US5707636A (en) * 1994-08-03 1998-01-13 Saitec S.R.L. Apparatus and method for preparing solid forms with controlled release of the active ingredient
US6387995B1 (en) * 1994-10-24 2002-05-14 Amcol International Corporation Precipitation polymerization process for producing an oil adsorbent polymer capable of entrapping solid particles and liquids and the product thereof
US20040081694A1 (en) * 1994-11-04 2004-04-29 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US5741519A (en) * 1995-03-21 1998-04-21 Basf Aktiengesellschaft The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6337319B1 (en) * 1995-08-18 2002-01-08 Wuyi Wang μ-Selective opioid peptides
US8144838B2 (en) * 1995-09-15 2012-03-27 At&T Intellectual Property Ii, L.P. Automated task classification system
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US6183781B1 (en) * 1996-05-14 2001-02-06 Alkermes Controlled Therapeutics, Inc. Method for fabricating polymer-based controlled-release devices
US6051253A (en) * 1996-07-23 2000-04-18 Basf Aktiengesellschaft Production of solid drug forms
US6399100B1 (en) * 1997-08-01 2002-06-04 Elan Corporation, Plc Controlled release pharmaceutical compositions containing tiagabine
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6547977B1 (en) * 1998-04-02 2003-04-15 Applied Materials Inc. Method for etching low k dielectrics
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6569506B1 (en) * 1998-08-27 2003-05-27 Chevron Chemical Company Llc Oxygen scavenging packaging
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20050095291A1 (en) * 2000-02-08 2005-05-05 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20110097404A1 (en) * 2000-02-08 2011-04-28 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20030008409A1 (en) * 2001-07-03 2003-01-09 Spearman Steven R. Method and apparatus for determining sunlight exposure
US20030069263A1 (en) * 2001-07-18 2003-04-10 Breder Christopher D. Pharmaceutical combinations of oxycodone and naloxone
US20030068370A1 (en) * 2001-08-06 2003-04-10 Richard Sackler Pharmaceutical formulation containing irritant
US20120108622A1 (en) * 2001-08-06 2012-05-03 Purdue Pharma L.P. Pharmaceutical formulation containing gelling agent
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030064099A1 (en) * 2001-08-06 2003-04-03 Benjamin Oshlack Pharmaceutical formulation containing bittering agent
US20030068371A1 (en) * 2001-08-06 2003-04-10 Benjamin Oshlack Pharmaceutical formulation containing opioid agonist,opioid antagonist and gelling agent
US7157103B2 (en) * 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20090081287A1 (en) * 2001-08-06 2009-03-26 Purdue Pharma L.P. Pharmaceutical Composition Containing Gelling Agent
US7214385B2 (en) * 2001-08-06 2007-05-08 Thomas J. Gruber Pharmaceutical formulation containing dye
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20090017121A1 (en) * 2001-10-25 2009-01-15 Bret Berner Gastric retained gabapentin dosage form
US20030104053A1 (en) * 2001-10-25 2003-06-05 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
US6753009B2 (en) * 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20060073102A1 (en) * 2002-05-13 2006-04-06 Huaihung Kao D Abuse-resistant opioid solid dosage form
US20120135071A1 (en) * 2002-06-17 2012-05-31 Grunenthal Gmbh Abuse-proofed dosage form
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US20100098758A1 (en) * 2002-10-25 2010-04-22 Gruenenthal Gmbh Abuse-Resistant Dosage Form
US20060004034A1 (en) * 2002-11-11 2006-01-05 Gruenenthal Gmbh Spirocyclic cyclohexane compounds
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
US20150079150A1 (en) * 2003-03-26 2015-03-19 Egalet Ltd. Morphine controlled release system
US20120034171A1 (en) * 2003-08-06 2012-02-09 Gruenenthal Gmbh Abuse-proofed dosage form
US20050031546A1 (en) * 2003-08-06 2005-02-10 Johannes Bartholomaus Abuse-proffed dosage form
US8114383B2 (en) * 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US20120107250A1 (en) * 2003-08-06 2012-05-03 Gruenenthal Gmbh Abuse-proofed dosage form
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US8101630B2 (en) * 2003-11-26 2012-01-24 Acura Pharmaceuticals, Inc. Extended release opioid abuse deterrent compositions and methods of making same
US7510726B2 (en) * 2003-11-26 2009-03-31 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20090005408A1 (en) * 2003-12-24 2009-01-01 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US7674799B2 (en) * 2004-03-30 2010-03-09 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US7683072B2 (en) * 2004-03-30 2010-03-23 Purdue Pharma L.P. Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US20070065365A1 (en) * 2004-04-21 2007-03-22 Gruenenthal Gmbh Abuse-resistant transdermal system
US20060017916A1 (en) * 2004-06-09 2006-01-26 Clarke Allan J Apparatus for producing a pharmaceutical product
US20060002859A1 (en) * 2004-07-01 2006-01-05 Elisabeth Arkenau Process for production of an abuse-proofed solid dosage form
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US8114384B2 (en) * 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20060012701A1 (en) * 2004-07-19 2006-01-19 Samsung Electronics Co., Ltd. Auto-stabilization method in control of driving image pickup device and reading memory and photographing apparatus having the same
US7647800B2 (en) * 2004-07-30 2010-01-19 Snecma Shot, devices, and installations for ultrasonic peening, and parts treated thereby
US20080131503A1 (en) * 2005-02-10 2008-06-05 Per Holm Stable Pharmaceutical Composition Comprising a Fixed Dose Combination of Fenofibrate and an Hmg-Coa Reductase Inhibitor
US7939543B2 (en) * 2005-03-04 2011-05-10 Purdue Pharma L.P. Method of reducing α, β unsaturated ketones in opioid compositions
US8445023B2 (en) * 2005-11-10 2013-05-21 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20100092553A1 (en) * 2005-11-10 2010-04-15 Flamel Technologies anti-misuse microparticulate oral pharmaceutical form
US20090011016A1 (en) * 2006-03-01 2009-01-08 Ethypharm Sa Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US20080081290A1 (en) * 2006-09-25 2008-04-03 Fujifilm Corporation Resist composition, resin for use in the resist composition, compound for use in the synthesis of the resin, and pattern-forming method using the resist composition
US20090318395A1 (en) * 2006-12-22 2009-12-24 Grunenthal Gmbh 3-hydroxychlormadinone acetate for the topical treatment of androgen-dependent skin diseases
US20090004267A1 (en) * 2007-03-07 2009-01-01 Gruenenthal Gmbh Dosage Form with Impeded Abuse
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8383152B2 (en) * 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US20140186440A1 (en) * 2008-03-11 2014-07-03 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20110020454A1 (en) * 2008-03-13 2011-01-27 Rosa Lamarca Casado Novel dosage and formulation
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US20110092515A1 (en) * 2008-07-03 2011-04-21 Zhihui Qiu Melt granulation process
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
US20100104638A1 (en) * 2008-10-27 2010-04-29 Wei-Guo Dai Extended release oral acetaminophen/tramadol dosage form
US20120136021A1 (en) * 2009-07-22 2012-05-31 Grunenthal Gmbh Oxidation-stabilized tamper-resistant dosage form
US20110038930A1 (en) * 2009-07-22 2011-02-17 Grunenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US20110129535A1 (en) * 2009-12-01 2011-06-02 Noven Pharmaceuticals, Inc. Transdermal testosterone device and delivery
US20120065220A1 (en) * 2010-09-02 2012-03-15 Grunenthal Gmbh Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20120059065A1 (en) * 2010-09-02 2012-03-08 Grünenthal GmbH Tamper Resistant Dosage Form Comprising An Anionic Polymer
US20130028970A1 (en) * 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US20130090349A1 (en) * 2011-10-06 2013-04-11 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
US20130129826A1 (en) * 2011-11-17 2013-05-23 Gruenenthal Gmbh Tamper-resistant oral pharmaceutical dosage form comprising opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
POLYOX, COLORCON, Application Data (4/2009) downloaded from http://www.colorcon.com/literature/marketing/ mr/Extended%20Release/POLYOX/English/ads_PEO_Antioxidant.pdf 4/28/2014 *
Salomies et al., Journal of AOAC International, 83: 1497-1501 (2000) *
Yeh et al., Journal of Pharmaceutical Sciences, 50(1): 35-42 (1961). *

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694080B2 (en) 2001-09-21 2017-07-04 Egalet Ltd. Polymer release system
US9707179B2 (en) 2001-09-21 2017-07-18 Egalet Ltd. Opioid polymer release system
US8808745B2 (en) 2001-09-21 2014-08-19 Egalet Ltd. Morphine polymer release system
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9884029B2 (en) 2003-03-26 2018-02-06 Egalet Ltd. Morphine controlled release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US20060193782A1 (en) * 2003-08-06 2006-08-31 Johannes Bartholomaus Abuse-proofed dosage form
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US20070183979A1 (en) * 2003-08-06 2007-08-09 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8420056B2 (en) 2003-08-06 2013-04-16 Grunenthal Gmbh Abuse-proofed dosage form
US8309060B2 (en) 2003-08-06 2012-11-13 Grunenthal Gmbh Abuse-proofed dosage form
US8192722B2 (en) 2003-08-06 2012-06-05 Grunenthal Gmbh Abuse-proof dosage form
US20080247959A1 (en) * 2003-08-06 2008-10-09 Grunenthal Gmbh Form of administration secured against misuse
US20080311049A1 (en) * 2003-08-06 2008-12-18 Grunenthal Gmbh Abuse-proof dosage form
US8114383B2 (en) 2003-08-06 2012-02-14 Gruenenthal Gmbh Abuse-proofed dosage form
US20090005408A1 (en) * 2003-12-24 2009-01-01 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20060002860A1 (en) * 2004-07-01 2006-01-05 Johannes Bartholomaus Abuse-proofed oral dosage form
US20060039864A1 (en) * 2004-07-01 2006-02-23 Johannes Bartholomaus Abuse-proofed oral dosage form
US8114384B2 (en) 2004-07-01 2012-02-14 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20080312264A1 (en) * 2004-07-01 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US8323889B2 (en) 2004-07-01 2012-12-04 Gruenenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20100151028A1 (en) * 2005-02-04 2010-06-17 Grunenthal Gmbh Crush resistant delayed-release dosage forms
US20080311197A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Process for the production of an abuse-proofed dosage form
US20080311187A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US9642809B2 (en) 2007-06-04 2017-05-09 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20090052818A1 (en) * 2007-07-10 2009-02-26 Jason Matthew Mitmesser Hybrid bearing
US20090202634A1 (en) * 2008-01-25 2009-08-13 Grunenthal Gmbh Pharmaceutical dosage form
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100015222A1 (en) * 2008-03-11 2010-01-21 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100196474A1 (en) * 2008-03-11 2010-08-05 Depomed, Inc. Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
US8668929B2 (en) 2008-03-11 2014-03-11 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8394408B2 (en) 2008-03-11 2013-03-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20110082214A1 (en) * 2008-05-09 2011-04-07 Gruenthal Gmbh Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9579285B2 (en) 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9872837B2 (en) 2010-12-22 2018-01-23 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9744136B2 (en) 2010-12-22 2017-08-29 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9861584B2 (en) 2010-12-22 2018-01-09 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9750703B2 (en) 2010-12-22 2017-09-05 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9895317B2 (en) 2010-12-23 2018-02-20 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US9539328B2 (en) 2011-05-17 2017-01-10 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9433582B2 (en) 2011-05-17 2016-09-06 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9468636B2 (en) 2011-05-17 2016-10-18 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US9629837B2 (en) 2011-05-17 2017-04-25 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130225625A1 (en) * 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013127830A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
US9044402B2 (en) 2012-07-06 2015-06-02 Egalet Ltd. Abuse-deterrent pharmaceutical compositions for controlled release
WO2014011830A1 (en) * 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US20140017310A1 (en) * 2012-07-12 2014-01-16 Mallinckrodt Llc Extended Release, Abuse Deterrent Pharmaceutical Compositions
US9730885B2 (en) * 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9662399B2 (en) 2013-02-05 2017-05-30 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9545448B2 (en) 2013-02-05 2017-01-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9655971B2 (en) 2013-02-05 2017-05-23 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9248229B2 (en) * 2013-03-14 2016-02-02 Becton, Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
US9545473B2 (en) 2013-03-14 2017-01-17 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
US20140262883A1 (en) * 2013-03-14 2014-09-18 Becton Dickinson France S.A.S. Packaging system for oxygen-sensitive drugs
US9301918B2 (en) 2013-03-15 2016-04-05 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9522119B2 (en) 2014-07-15 2016-12-20 Isa Odidi Compositions and methods for reducing overdose
US9801939B2 (en) 2014-07-15 2017-10-31 Isa Odidi Compositions and methods for reducing overdose
US9700515B2 (en) 2014-07-15 2017-07-11 Isa Odidi Compositions and methods for reducing overdose
US9700516B2 (en) 2014-07-15 2017-07-11 Isa Odidi Compositions and methods for reducing overdose
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2017070566A1 (en) * 2015-10-23 2017-04-27 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone

Also Published As

Publication number Publication date Type
WO2011009603A8 (en) 2011-12-15 application
CA2767888C (en) 2017-09-12 grant
KR101747156B1 (en) 2017-06-27 grant
RU2012106166A (en) 2013-08-27 application
US20150366809A1 (en) 2015-12-24 application
EP2456424A1 (en) 2012-05-30 application
RU2555531C2 (en) 2015-07-10 grant
US20120136021A1 (en) 2012-05-31 application
EP2997965A1 (en) 2016-03-23 application
JP2012533585A (en) 2012-12-27 application
EP2456425B1 (en) 2015-10-21 grant
CN102639118A (en) 2012-08-15 application
CA2767888A1 (en) 2011-01-27 application
US20140194455A1 (en) 2014-07-10 application
WO2011009604A1 (en) 2011-01-27 application
JP2012533586A (en) 2012-12-27 application
KR20120050975A (en) 2012-05-21 application
RU2012106167A (en) 2013-08-27 application
WO2011009603A1 (en) 2011-01-27 application
CA2766172A1 (en) 2011-01-27 application
CN102573806B (en) 2015-02-25 grant
CN102639118B (en) 2015-07-29 grant
US9925146B2 (en) 2018-03-27 grant
CN102573806A (en) 2012-07-11 application
EP2456424B1 (en) 2013-08-28 grant
EP2662076A1 (en) 2013-11-13 application
ES2560210T3 (en) 2016-02-17 grant
KR20120038979A (en) 2012-04-24 application
RU2567723C2 (en) 2015-11-10 grant
CA2766172C (en) 2017-09-12 grant
EP2456425A1 (en) 2012-05-30 application
ES2428938T3 (en) 2013-11-12 grant

Similar Documents

Publication Publication Date Title
US8192722B2 (en) Abuse-proof dosage form
US6399100B1 (en) Controlled release pharmaceutical compositions containing tiagabine
US20080031901A1 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
US7510726B2 (en) Methods and compositions for deterring abuse of opioid containing dosage forms
US20090011016A1 (en) Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion
US8114384B2 (en) Process for the production of an abuse-proofed solid dosage form
US20070190142A1 (en) Dosage forms for the delivery of drugs of abuse and related methods
US20030099704A1 (en) Controlled release oxycodone compositions
US20120202838A1 (en) Drug formulations
US8383152B2 (en) Pharmaceutical dosage form
US20110229526A1 (en) Formulations of nonopioid and confined opioid analgesics
US20080319085A1 (en) Titration dosing regimen for controlled release tramadol
US20060153915A1 (en) Sustained-release preparations and method for producing the same
WO2006002884A1 (en) Oral dosage form safeguarded against abuse
US20100203130A1 (en) Pharmaceutical compositions resistant to abuse
WO2012076907A2 (en) Dosage form
KR20070111510A (en) Break-resistant delayed release forms of administration
US20110038930A1 (en) Hot-melt extruded pharmaceutical dosage form
US20130028970A1 (en) Tamper-resistant tablet providing immediate drug release
US20110150991A1 (en) Abuse resistant drugs, method of use and method of making
US20120135075A1 (en) Dosage form
US20100034876A1 (en) Controlled release oxycodone compositions
US6569455B1 (en) Quick-release extrudates, method for preparing the same and compositions obtained from said extrudates
US20110212173A1 (en) Controlled Release Treatment of Depression
US20130209557A1 (en) Tamper resistant dosage form comprising inorganic salt

Legal Events

Date Code Title Description
AS Assignment

Owner name: GRUNENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARTHOLOMAUS, JOHANNES;GEISSLER, ANJA;BERTRAM, ULRIKE;AND OTHERS;SIGNING DATES FROM 20100916 TO 20100922;REEL/FRAME:025083/0859

AS Assignment

Owner name: GRUENENTHAL GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BICANE, FATIMA;REEL/FRAME:040596/0338

Effective date: 20160523